Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,28205288,half-life,"The mean half-life of the RBV-DOE and RBV-Gel was 27.949 ± 2.783 h and 37.374 ± 3.502 h, respectively.",Hematological adverse effects and pharmacokinetics of ribavirin in pigs following intramuscular administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28205288/),h,27.949,1881,DB00811,Ribavirin
,28205288,half-life,"The mean half-life of the RBV-DOE and RBV-Gel was 27.949 ± 2.783 h and 37.374 ± 3.502 h, respectively.",Hematological adverse effects and pharmacokinetics of ribavirin in pigs following intramuscular administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28205288/),h,37.374,1882,DB00811,Ribavirin
,28205288,peak serum concentration (Cmax ),"The mean peak serum concentration (Cmax ) and area under the serum concentration-time curve from time zero to infinity (AUCinf ) of RBV-DOE were 8340.000 ± 2562.577 ng/mL and 16 0095.430 ± 61 253.400 h·ng/mL, respectively.",Hematological adverse effects and pharmacokinetics of ribavirin in pigs following intramuscular administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28205288/),[ng] / [ml],8340.000,1883,DB00811,Ribavirin
,28205288,area under the serum concentration-time curve from time zero to infinity (AUCinf ),"The mean peak serum concentration (Cmax ) and area under the serum concentration-time curve from time zero to infinity (AUCinf ) of RBV-DOE were 8340.000 ± 2562.577 ng/mL and 16 0095.430 ± 61 253.400 h·ng/mL, respectively.",Hematological adverse effects and pharmacokinetics of ribavirin in pigs following intramuscular administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28205288/),[h·ng] / [ml],16 0095.430,1884,DB00811,Ribavirin
,28205288,Cmax,"The Cmax and AUCinf of RBV-Gel were 15 300.000 ± 3764.306 ng/mL and 207526.260 ± 63656.390 h·ng/mL, respectively.",Hematological adverse effects and pharmacokinetics of ribavirin in pigs following intramuscular administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28205288/),[ng] / [ml],15 300.000,1885,DB00811,Ribavirin
,28205288,AUCinf,"The Cmax and AUCinf of RBV-Gel were 15 300.000 ± 3764.306 ng/mL and 207526.260 ± 63656.390 h·ng/mL, respectively.",Hematological adverse effects and pharmacokinetics of ribavirin in pigs following intramuscular administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28205288/),[h·ng] / [ml],207526.260,1886,DB00811,Ribavirin
,27077673,Cthrough,The ATV mean Cthrough fell from 763.8 ng/mL (CI 95%: 230.3-1297.3) without BOC to 507.7 ng/mL (CI 95%: 164-851.4) with BOC.,"Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27077673/),[ng] / [ml],763.8,3071,DB00811,Ribavirin
,27077673,Cthrough,The ATV mean Cthrough fell from 763.8 ng/mL (CI 95%: 230.3-1297.3) without BOC to 507.7 ng/mL (CI 95%: 164-851.4) with BOC.,"Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27077673/),[ng] / [ml],507.7,3072,DB00811,Ribavirin
,20308381,overall inhibition constant (K*(i)),It has an overall inhibition constant (K*(i)) of 7 nM and a dissociation half-life of 1 to 2 h.,"Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20308381/),nM,7,7020,DB00811,Ribavirin
,20308381,dissociation half-life,It has an overall inhibition constant (K*(i)) of 7 nM and a dissociation half-life of 1 to 2 h.,"Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20308381/),h,1 to 2,7021,DB00811,Ribavirin
,20308381,90% effective concentration (EC(90)),SCH 900518 inhibited replicon RNA at a 90% effective concentration (EC(90)) of 40 nM.,"Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20308381/),nM,40,7022,DB00811,Ribavirin
≤,27584548,"AUC24,ss ratio","Opioids, antipsychotics, anti-epileptics, antidiabetics and non-ethinyl estradiol-containing hormone replacement therapies appeared to have an effect (AUC24,ss ratio ≤0.5 or ≥2.0) on paritaprevir exposures.","Effect of co-medications on paritaprevir, ritonavir, ombitasvir, dasabuvir and ribavirin pharmacokinetics: analysis of data from seven Phase II/III trials. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27584548/),,0.5,8521,DB00811,Ribavirin
≥,27584548,"AUC24,ss ratio","Opioids, antipsychotics, anti-epileptics, antidiabetics and non-ethinyl estradiol-containing hormone replacement therapies appeared to have an effect (AUC24,ss ratio ≤0.5 or ≥2.0) on paritaprevir exposures.","Effect of co-medications on paritaprevir, ritonavir, ombitasvir, dasabuvir and ribavirin pharmacokinetics: analysis of data from seven Phase II/III trials. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27584548/),,2.0,8522,DB00811,Ribavirin
,24096565,T(1/2α),"After single-dose administration, T(1/2α) ranged from 0.20 to 0.55 h, AUC(0-12) from 1.81 to 43.6 μg mL(-1) h(-1), V(d) from 228 to 55.9 mL kg(-1), and CL from 220 to 36.5 mL kg(-1) h(-1) (P < 0.01).",Determination and pharmacokinetic study of the diacid metabolite of norcantharidin in beagle plasma by use of liquid chromatography-tandem mass spectrometry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24096565/),h,0.20 to 0.55,9923,DB00811,Ribavirin
,24096565,AUC(0-12),"After single-dose administration, T(1/2α) ranged from 0.20 to 0.55 h, AUC(0-12) from 1.81 to 43.6 μg mL(-1) h(-1), V(d) from 228 to 55.9 mL kg(-1), and CL from 220 to 36.5 mL kg(-1) h(-1) (P < 0.01).",Determination and pharmacokinetic study of the diacid metabolite of norcantharidin in beagle plasma by use of liquid chromatography-tandem mass spectrometry. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24096565/),[μg] / [h·ml],1.81 to 43.6,9924,DB00811,Ribavirin
,24096565,V(d),"After single-dose administration, T(1/2α) ranged from 0.20 to 0.55 h, AUC(0-12) from 1.81 to 43.6 μg mL(-1) h(-1), V(d) from 228 to 55.9 mL kg(-1), and CL from 220 to 36.5 mL kg(-1) h(-1) (P < 0.01).",Determination and pharmacokinetic study of the diacid metabolite of norcantharidin in beagle plasma by use of liquid chromatography-tandem mass spectrometry. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24096565/),[ml] / [kg],228 to 55.9,9925,DB00811,Ribavirin
,24096565,CL,"After single-dose administration, T(1/2α) ranged from 0.20 to 0.55 h, AUC(0-12) from 1.81 to 43.6 μg mL(-1) h(-1), V(d) from 228 to 55.9 mL kg(-1), and CL from 220 to 36.5 mL kg(-1) h(-1) (P < 0.01).",Determination and pharmacokinetic study of the diacid metabolite of norcantharidin in beagle plasma by use of liquid chromatography-tandem mass spectrometry. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24096565/),[ml] / [h·kg],220 to 36.5,9926,DB00811,Ribavirin
,9108860,Plasma concentrations at steady state,"Plasma concentrations at steady state were 4.81 to 8.47 micrograms/ml, hemofiltration sieving-coefficient was 0.85, and hemofiltration clearance (0.046 L/kg per hour) was similar to the renal clearance reported with normal kidney function.",Intravenous ribavirin therapy in a neonate with disseminated adenovirus infection undergoing extracorporeal membrane oxygenation: pharmacokinetics and clearance by hemofiltration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9108860/),[μg] / [ml],4.81 to 8.47,22422,DB00811,Ribavirin
,9108860,sieving-coefficient,"Plasma concentrations at steady state were 4.81 to 8.47 micrograms/ml, hemofiltration sieving-coefficient was 0.85, and hemofiltration clearance (0.046 L/kg per hour) was similar to the renal clearance reported with normal kidney function.",Intravenous ribavirin therapy in a neonate with disseminated adenovirus infection undergoing extracorporeal membrane oxygenation: pharmacokinetics and clearance by hemofiltration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9108860/),,0.85,22423,DB00811,Ribavirin
,9108860,hemofiltration clearance,"Plasma concentrations at steady state were 4.81 to 8.47 micrograms/ml, hemofiltration sieving-coefficient was 0.85, and hemofiltration clearance (0.046 L/kg per hour) was similar to the renal clearance reported with normal kidney function.",Intravenous ribavirin therapy in a neonate with disseminated adenovirus infection undergoing extracorporeal membrane oxygenation: pharmacokinetics and clearance by hemofiltration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9108860/),[l] / [h·kg],0.046,22424,DB00811,Ribavirin
,3986760,clearance,The mean clearance of tiazofurin from plasma was 70 +/- 23 (SD) ml/min/sq m after a dose of 100 mg/kg and 106 +/- 38 ml/min/sq m after a dose of 500 mg/kg with no evidence of dose dependency.,Pharmacokinetics of tiazofurin in the plasma and cerebrospinal fluid of rhesus monkeys. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3986760/),[ml] / [m·min·sq],70,24144,DB00811,Ribavirin
,3986760,clearance,The mean clearance of tiazofurin from plasma was 70 +/- 23 (SD) ml/min/sq m after a dose of 100 mg/kg and 106 +/- 38 ml/min/sq m after a dose of 500 mg/kg with no evidence of dose dependency.,Pharmacokinetics of tiazofurin in the plasma and cerebrospinal fluid of rhesus monkeys. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3986760/),[ml] / [m·min·sq],106,24145,DB00811,Ribavirin
,3986760,t 1/2 alpha,"The t 1/2 alpha was 0.23 h, t 1/2 beta was 1.9 to 2.0 h, and t 1/2 gamma was 6.8 to 7.1 h.",Pharmacokinetics of tiazofurin in the plasma and cerebrospinal fluid of rhesus monkeys. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3986760/),h,0.23,24146,DB00811,Ribavirin
,3986760,t 1/2 beta,"The t 1/2 alpha was 0.23 h, t 1/2 beta was 1.9 to 2.0 h, and t 1/2 gamma was 6.8 to 7.1 h.",Pharmacokinetics of tiazofurin in the plasma and cerebrospinal fluid of rhesus monkeys. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3986760/),h,1.9 to 2.0,24147,DB00811,Ribavirin
,3986760,t 1/2 gamma,"The t 1/2 alpha was 0.23 h, t 1/2 beta was 1.9 to 2.0 h, and t 1/2 gamma was 6.8 to 7.1 h.",Pharmacokinetics of tiazofurin in the plasma and cerebrospinal fluid of rhesus monkeys. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3986760/),h,6.8 to 7.1,24148,DB00811,Ribavirin
,7840556,elimination half-life,"GG167 was metabolically stable, with an elimination half-life of 10 min following intravenous administration.","Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7840556/),min,10,25260,DB00811,Ribavirin
,3986813,terminal half-life,Plasma clearance of Tiazofurin followed a biexponential pattern with a harmonic mean terminal half-life of 7.6 h.,"Phase I evaluation and pharmacokinetics of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, NSC 286193). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3986813/),h,7.6,35435,DB00811,Ribavirin
,3986813,volume of distribution at steady state,"The mean volume of distribution at steady state was 30 liters/sq m, and the mean plasma clearance was 3 liters/h/sq m.","Phase I evaluation and pharmacokinetics of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, NSC 286193). ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3986813/),[l] / [m·sq],30,35436,DB00811,Ribavirin
,3986813,plasma clearance,"The mean volume of distribution at steady state was 30 liters/sq m, and the mean plasma clearance was 3 liters/h/sq m.","Phase I evaluation and pharmacokinetics of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, NSC 286193). ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3986813/),[l] / [h·m·sq],3,35437,DB00811,Ribavirin
,3986813,total cumulative urinary excretion,The total cumulative urinary excretion ranged from 15 to 49%.,"Phase I evaluation and pharmacokinetics of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, NSC 286193). ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3986813/),%,15 to 49,35438,DB00811,Ribavirin
,24092661,Ctrough levels,"The mean telaprevir Ctrough levels at days 3, 7 and 14 of SVR patients (2.748, 2.733 and 2.999 μg/mL, respectively) were significantly higher than those of non-SVR patients (1.616, 1.788 and 2.314 μg/mL, respectively) (all P < 0.05).",Therapeutic drug monitoring of telaprevir in chronic hepatitis C patients receiving telaprevir-based triple therapy is useful for predicting virological response. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24092661/),[μg] / [ml],2.748,40515,DB00811,Ribavirin
,24092661,Ctrough levels,"The mean telaprevir Ctrough levels at days 3, 7 and 14 of SVR patients (2.748, 2.733 and 2.999 μg/mL, respectively) were significantly higher than those of non-SVR patients (1.616, 1.788 and 2.314 μg/mL, respectively) (all P < 0.05).",Therapeutic drug monitoring of telaprevir in chronic hepatitis C patients receiving telaprevir-based triple therapy is useful for predicting virological response. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24092661/),[μg] / [ml],2.733,40516,DB00811,Ribavirin
,24092661,Ctrough levels,"The mean telaprevir Ctrough levels at days 3, 7 and 14 of SVR patients (2.748, 2.733 and 2.999 μg/mL, respectively) were significantly higher than those of non-SVR patients (1.616, 1.788 and 2.314 μg/mL, respectively) (all P < 0.05).",Therapeutic drug monitoring of telaprevir in chronic hepatitis C patients receiving telaprevir-based triple therapy is useful for predicting virological response. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24092661/),[μg] / [ml],2.999,40517,DB00811,Ribavirin
,24092661,Ctrough levels,"The mean telaprevir Ctrough levels at days 3, 7 and 14 of SVR patients (2.748, 2.733 and 2.999 μg/mL, respectively) were significantly higher than those of non-SVR patients (1.616, 1.788 and 2.314 μg/mL, respectively) (all P < 0.05).",Therapeutic drug monitoring of telaprevir in chronic hepatitis C patients receiving telaprevir-based triple therapy is useful for predicting virological response. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24092661/),[μg] / [ml],1.616,40518,DB00811,Ribavirin
,24092661,Ctrough levels,"The mean telaprevir Ctrough levels at days 3, 7 and 14 of SVR patients (2.748, 2.733 and 2.999 μg/mL, respectively) were significantly higher than those of non-SVR patients (1.616, 1.788 and 2.314 μg/mL, respectively) (all P < 0.05).",Therapeutic drug monitoring of telaprevir in chronic hepatitis C patients receiving telaprevir-based triple therapy is useful for predicting virological response. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24092661/),[μg] / [ml],1.788,40519,DB00811,Ribavirin
,24092661,Ctrough levels,"The mean telaprevir Ctrough levels at days 3, 7 and 14 of SVR patients (2.748, 2.733 and 2.999 μg/mL, respectively) were significantly higher than those of non-SVR patients (1.616, 1.788 and 2.314 μg/mL, respectively) (all P < 0.05).",Therapeutic drug monitoring of telaprevir in chronic hepatitis C patients receiving telaprevir-based triple therapy is useful for predicting virological response. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24092661/),[μg] / [ml],2.314,40520,DB00811,Ribavirin
,20561702,cell loss rate (delta),"The maximum PEG-IFN effectiveness during the first PEG-IFN dose and the HCV-infected cell loss rate (delta), were significantly higher in SVRs compared to non-SVRs (median 95% vs. 86% [p=0.013], 0.27 vs. 0.11 day(-1) [p=0.006], respectively).",Pharmacodynamics of PEG-IFN-alpha-2a in HIV/HCV co-infected patients: implications for treatment outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20561702/),1/[day],0.27,41009,DB00811,Ribavirin
,20561702,cell loss rate (delta),"The maximum PEG-IFN effectiveness during the first PEG-IFN dose and the HCV-infected cell loss rate (delta), were significantly higher in SVRs compared to non-SVRs (median 95% vs. 86% [p=0.013], 0.27 vs. 0.11 day(-1) [p=0.006], respectively).",Pharmacodynamics of PEG-IFN-alpha-2a in HIV/HCV co-infected patients: implications for treatment outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20561702/),1/[day],0.11,41010,DB00811,Ribavirin
,20561702,delta,Genotype 1 had a significantly lower delta compared to genotype 3 (median 0.14 vs. 0.23 day(-1) [p=0.021]).,Pharmacodynamics of PEG-IFN-alpha-2a in HIV/HCV co-infected patients: implications for treatment outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20561702/),1/[day],0.14,41011,DB00811,Ribavirin
,20561702,delta,Genotype 1 had a significantly lower delta compared to genotype 3 (median 0.14 vs. 0.23 day(-1) [p=0.021]).,Pharmacodynamics of PEG-IFN-alpha-2a in HIV/HCV co-infected patients: implications for treatment outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20561702/),1/[day],0.23,41012,DB00811,Ribavirin
,20561702,EC(50),The PEG-IFN concentration that decreased HCV production by 50% (EC(50)) was lower in genotype 3 compared to genotype 1 (median 1.3 vs. 3.4 [p=0.034]).,Pharmacodynamics of PEG-IFN-alpha-2a in HIV/HCV co-infected patients: implications for treatment outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20561702/),,1.3,41013,DB00811,Ribavirin
,20561702,EC(50),The PEG-IFN concentration that decreased HCV production by 50% (EC(50)) was lower in genotype 3 compared to genotype 1 (median 1.3 vs. 3.4 [p=0.034]).,Pharmacodynamics of PEG-IFN-alpha-2a in HIV/HCV co-infected patients: implications for treatment outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20561702/),,3.4,41014,DB00811,Ribavirin
above,2200759,peak,These observations suggest that both high peak plasma concentrations (above 400 microM) and prolonged exposure to plasma levels exceeding 50 microM may result in a higher incidence of serious non-hematologic toxicity.,Clinical toxicity associated with tiazofurin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2200759/),μM,400,41278,DB00811,Ribavirin
,24005956,rapid virologic response rates,"High rapid virologic response rates (83, 90, and 8 % for simeprevir 50 mg combined, 100 mg combined, and PR48 groups, respectively) led to high sustained virologic response rates (77-92 %, compared with 46 % for PR48).",Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24005956/),%,83,42354,DB00811,Ribavirin
,24005956,rapid virologic response rates,"High rapid virologic response rates (83, 90, and 8 % for simeprevir 50 mg combined, 100 mg combined, and PR48 groups, respectively) led to high sustained virologic response rates (77-92 %, compared with 46 % for PR48).",Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24005956/),%,90,42355,DB00811,Ribavirin
,24005956,rapid virologic response rates,"High rapid virologic response rates (83, 90, and 8 % for simeprevir 50 mg combined, 100 mg combined, and PR48 groups, respectively) led to high sustained virologic response rates (77-92 %, compared with 46 % for PR48).",Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24005956/),%,8,42356,DB00811,Ribavirin
,24005956,sustained v,"High rapid virologic response rates (83, 90, and 8 % for simeprevir 50 mg combined, 100 mg combined, and PR48 groups, respectively) led to high sustained virologic response rates (77-92 %, compared with 46 % for PR48).",Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24005956/),%,77-92,42357,DB00811,Ribavirin
,24005956,sustained v,"High rapid virologic response rates (83, 90, and 8 % for simeprevir 50 mg combined, 100 mg combined, and PR48 groups, respectively) led to high sustained virologic response rates (77-92 %, compared with 46 % for PR48).",Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24005956/),%,46,42358,DB00811,Ribavirin
,24005956,Relapse rates,"Relapse rates in simeprevir-treated patients were low (8-17 %, compared with 36 % for the PR48 group).",Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24005956/),,8,42359,DB00811,Ribavirin
,24005956,Relapse rates,"Relapse rates in simeprevir-treated patients were low (8-17 %, compared with 36 % for the PR48 group).",Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24005956/),,36,42360,DB00811,Ribavirin
,17118126,clearance,"Lean body weight (range 41-91 kg) was the only covariate with a clinically significant influence on ribavirin pharmacokinetics, affecting clearance (15.3-23.9 l h(-1)) and the volume of the larger peripheral compartment.",Pharmacokinetics of ribavirin in patients with hepatitis C virus. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17118126/),[l] / [h],15.3-23.9,51751,DB00811,Ribavirin
,26869690,trough concentrations,"Mean ± SD plasma ribavirin trough concentrations (μg/mL) on days 14, 28, 42 and 56, respectively, were not significantly different with coadministration of abacavir (1.54 ± 0.60, 1.93 ± 0.54, 2.14 ± 0.73 and 2.54 ± 1.05) compared with ribavirin alone (1.48 ± 0.32, 2.08 ± 0.41, 2.32 ± 0.47 and 2.60 ± 0.62) (P > 0.40).",Plasma and intracellular ribavirin concentrations are not significantly altered by abacavir in hepatitis C virus-infected patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26869690/),[μg] / [ml],1.54,52682,DB00811,Ribavirin
,26869690,trough concentrations,"Mean ± SD plasma ribavirin trough concentrations (μg/mL) on days 14, 28, 42 and 56, respectively, were not significantly different with coadministration of abacavir (1.54 ± 0.60, 1.93 ± 0.54, 2.14 ± 0.73 and 2.54 ± 1.05) compared with ribavirin alone (1.48 ± 0.32, 2.08 ± 0.41, 2.32 ± 0.47 and 2.60 ± 0.62) (P > 0.40).",Plasma and intracellular ribavirin concentrations are not significantly altered by abacavir in hepatitis C virus-infected patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26869690/),[μg] / [ml],1.93,52683,DB00811,Ribavirin
,26869690,trough concentrations,"Mean ± SD plasma ribavirin trough concentrations (μg/mL) on days 14, 28, 42 and 56, respectively, were not significantly different with coadministration of abacavir (1.54 ± 0.60, 1.93 ± 0.54, 2.14 ± 0.73 and 2.54 ± 1.05) compared with ribavirin alone (1.48 ± 0.32, 2.08 ± 0.41, 2.32 ± 0.47 and 2.60 ± 0.62) (P > 0.40).",Plasma and intracellular ribavirin concentrations are not significantly altered by abacavir in hepatitis C virus-infected patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26869690/),[μg] / [ml],2.14,52684,DB00811,Ribavirin
,26869690,trough concentrations,"Mean ± SD plasma ribavirin trough concentrations (μg/mL) on days 14, 28, 42 and 56, respectively, were not significantly different with coadministration of abacavir (1.54 ± 0.60, 1.93 ± 0.54, 2.14 ± 0.73 and 2.54 ± 1.05) compared with ribavirin alone (1.48 ± 0.32, 2.08 ± 0.41, 2.32 ± 0.47 and 2.60 ± 0.62) (P > 0.40).",Plasma and intracellular ribavirin concentrations are not significantly altered by abacavir in hepatitis C virus-infected patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26869690/),[μg] / [ml],2.54,52685,DB00811,Ribavirin
,26869690,trough concentrations,"Mean ± SD plasma ribavirin trough concentrations (μg/mL) on days 14, 28, 42 and 56, respectively, were not significantly different with coadministration of abacavir (1.54 ± 0.60, 1.93 ± 0.54, 2.14 ± 0.73 and 2.54 ± 1.05) compared with ribavirin alone (1.48 ± 0.32, 2.08 ± 0.41, 2.32 ± 0.47 and 2.60 ± 0.62) (P > 0.40).",Plasma and intracellular ribavirin concentrations are not significantly altered by abacavir in hepatitis C virus-infected patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26869690/),[μg] / [ml],1.48,52686,DB00811,Ribavirin
,26869690,trough concentrations,"Mean ± SD plasma ribavirin trough concentrations (μg/mL) on days 14, 28, 42 and 56, respectively, were not significantly different with coadministration of abacavir (1.54 ± 0.60, 1.93 ± 0.54, 2.14 ± 0.73 and 2.54 ± 1.05) compared with ribavirin alone (1.48 ± 0.32, 2.08 ± 0.41, 2.32 ± 0.47 and 2.60 ± 0.62) (P > 0.40).",Plasma and intracellular ribavirin concentrations are not significantly altered by abacavir in hepatitis C virus-infected patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26869690/),[μg] / [ml],2.08,52687,DB00811,Ribavirin
,26869690,trough concentrations,"Mean ± SD plasma ribavirin trough concentrations (μg/mL) on days 14, 28, 42 and 56, respectively, were not significantly different with coadministration of abacavir (1.54 ± 0.60, 1.93 ± 0.54, 2.14 ± 0.73 and 2.54 ± 1.05) compared with ribavirin alone (1.48 ± 0.32, 2.08 ± 0.41, 2.32 ± 0.47 and 2.60 ± 0.62) (P > 0.40).",Plasma and intracellular ribavirin concentrations are not significantly altered by abacavir in hepatitis C virus-infected patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26869690/),[μg] / [ml],2.32,52688,DB00811,Ribavirin
,26869690,trough concentrations,"Mean ± SD plasma ribavirin trough concentrations (μg/mL) on days 14, 28, 42 and 56, respectively, were not significantly different with coadministration of abacavir (1.54 ± 0.60, 1.93 ± 0.54, 2.14 ± 0.73 and 2.54 ± 1.05) compared with ribavirin alone (1.48 ± 0.32, 2.08 ± 0.41, 2.32 ± 0.47 and 2.60 ± 0.62) (P > 0.40).",Plasma and intracellular ribavirin concentrations are not significantly altered by abacavir in hepatitis C virus-infected patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26869690/),[μg] / [ml],2.60,52689,DB00811,Ribavirin
,26869690,intracellular concentrations,"Mean ribavirin triphosphate intracellular concentrations (pmol/10(6) cells) on days 28 and 56, respectively, did not differ statistically between abacavir users (11.98 ± 9.86 and 15.87 ± 12.52) and non-users (15.91 ± 15.58 and 15.93 ± 12.69) (P > 0.4).",Plasma and intracellular ribavirin concentrations are not significantly altered by abacavir in hepatitis C virus-infected patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26869690/),[pM] / [10(6)·cells],11.98,52690,DB00811,Ribavirin
,26869690,intracellular concentrations,"Mean ribavirin triphosphate intracellular concentrations (pmol/10(6) cells) on days 28 and 56, respectively, did not differ statistically between abacavir users (11.98 ± 9.86 and 15.87 ± 12.52) and non-users (15.91 ± 15.58 and 15.93 ± 12.69) (P > 0.4).",Plasma and intracellular ribavirin concentrations are not significantly altered by abacavir in hepatitis C virus-infected patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26869690/),[pM] / [10(6)·cells],15.87,52691,DB00811,Ribavirin
,26869690,intracellular concentrations,"Mean ribavirin triphosphate intracellular concentrations (pmol/10(6) cells) on days 28 and 56, respectively, did not differ statistically between abacavir users (11.98 ± 9.86 and 15.87 ± 12.52) and non-users (15.91 ± 15.58 and 15.93 ± 12.69) (P > 0.4).",Plasma and intracellular ribavirin concentrations are not significantly altered by abacavir in hepatitis C virus-infected patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26869690/),[pM] / [10(6)·cells],15.91,52692,DB00811,Ribavirin
,26869690,intracellular concentrations,"Mean ribavirin triphosphate intracellular concentrations (pmol/10(6) cells) on days 28 and 56, respectively, did not differ statistically between abacavir users (11.98 ± 9.86 and 15.87 ± 12.52) and non-users (15.91 ± 15.58 and 15.93 ± 12.69) (P > 0.4).",Plasma and intracellular ribavirin concentrations are not significantly altered by abacavir in hepatitis C virus-infected patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26869690/),[pM] / [10(6)·cells],15.93,52693,DB00811,Ribavirin
,23190247,sustained virological response rates [SVR],"The antiviral effects were similar in the two groups (sustained virological response rates [SVR], 40% in group A, 50% in group B).",Exploratory study on telaprevir given every 8 h at 500 mg or 750 mg with peginterferon-alpha-2b and ribavirin in hepatitis C patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23190247/),%,40,54800,DB00811,Ribavirin
,23190247,sustained virological response rates [SVR],"The antiviral effects were similar in the two groups (sustained virological response rates [SVR], 40% in group A, 50% in group B).",Exploratory study on telaprevir given every 8 h at 500 mg or 750 mg with peginterferon-alpha-2b and ribavirin in hepatitis C patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23190247/),%,50,54801,DB00811,Ribavirin
,23190247,disco,The discontinuation rates by anemia were 30% in group A and 20% in group B.,Exploratory study on telaprevir given every 8 h at 500 mg or 750 mg with peginterferon-alpha-2b and ribavirin in hepatitis C patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23190247/),,30,54802,DB00811,Ribavirin
,23190247,disco,The discontinuation rates by anemia were 30% in group A and 20% in group B.,Exploratory study on telaprevir given every 8 h at 500 mg or 750 mg with peginterferon-alpha-2b and ribavirin in hepatitis C patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23190247/),,20,54803,DB00811,Ribavirin
,29214737,area under the plasma concentration-time curve (AUC),"Mean tenofovir area under the plasma concentration-time curve (AUC) at week 4 was high, with mean ± SD AUC variation between baseline and week 4 higher in cirrhotic than in noncirrhotic patients (3261.57 ± 1920.47 ng/mL vs. 1576.15 ± 911.97 ng/mL, respectively; P = 0.03).","Efficacy, safety and patient-reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor-experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study). ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29214737/),[ng] / [ml],3261.57,54999,DB00811,Ribavirin
,29214737,area under the plasma concentration-time curve (AUC),"Mean tenofovir area under the plasma concentration-time curve (AUC) at week 4 was high, with mean ± SD AUC variation between baseline and week 4 higher in cirrhotic than in noncirrhotic patients (3261.57 ± 1920.47 ng/mL vs. 1576.15 ± 911.97 ng/mL, respectively; P = 0.03).","Efficacy, safety and patient-reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor-experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study). ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29214737/),[ng] / [ml],1576.15,55000,DB00811,Ribavirin
,29214737,AUC,"Mean tenofovir area under the plasma concentration-time curve (AUC) at week 4 was high, with mean ± SD AUC variation between baseline and week 4 higher in cirrhotic than in noncirrhotic patients (3261.57 ± 1920.47 ng/mL vs. 1576.15 ± 911.97 ng/mL, respectively; P = 0.03).","Efficacy, safety and patient-reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor-experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study). ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29214737/),[ng] / [ml],3261.57,55001,DB00811,Ribavirin
,29214737,AUC,"Mean tenofovir area under the plasma concentration-time curve (AUC) at week 4 was high, with mean ± SD AUC variation between baseline and week 4 higher in cirrhotic than in noncirrhotic patients (3261.57 ± 1920.47 ng/mL vs. 1576.15 ± 911.97 ng/mL, respectively; P = 0.03).","Efficacy, safety and patient-reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor-experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study). ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29214737/),[ng] / [ml],1576.15,55002,DB00811,Ribavirin
,15703363,half-lives,Long half-lives for viramidine (66-76 hours in plasma and 200-420 hours in red blood cells) and ribavirin (340-410 hours in plasma and 360-430 hours in red blood cells) were noted.,"Ascending multiple-dose pharmacokinetics of viramidine, a prodrug of ribavirin, in adult subjects with compensated hepatitis C infection. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15703363/),h,66-76,59143,DB00811,Ribavirin
,15703363,half-lives,Long half-lives for viramidine (66-76 hours in plasma and 200-420 hours in red blood cells) and ribavirin (340-410 hours in plasma and 360-430 hours in red blood cells) were noted.,"Ascending multiple-dose pharmacokinetics of viramidine, a prodrug of ribavirin, in adult subjects with compensated hepatitis C infection. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15703363/),h,200-420,59144,DB00811,Ribavirin
,15703363,half-lives,Long half-lives for viramidine (66-76 hours in plasma and 200-420 hours in red blood cells) and ribavirin (340-410 hours in plasma and 360-430 hours in red blood cells) were noted.,"Ascending multiple-dose pharmacokinetics of viramidine, a prodrug of ribavirin, in adult subjects with compensated hepatitis C infection. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15703363/),h,340-410,59145,DB00811,Ribavirin
,15703363,half-lives,Long half-lives for viramidine (66-76 hours in plasma and 200-420 hours in red blood cells) and ribavirin (340-410 hours in plasma and 360-430 hours in red blood cells) were noted.,"Ascending multiple-dose pharmacokinetics of viramidine, a prodrug of ribavirin, in adult subjects with compensated hepatitis C infection. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15703363/),h,360-430,59146,DB00811,Ribavirin
,15703363,renal clearance,The renal clearance was low for both viramidine (5-8 L/h) and ribavirin (4-7 L/h).,"Ascending multiple-dose pharmacokinetics of viramidine, a prodrug of ribavirin, in adult subjects with compensated hepatitis C infection. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15703363/),[l] / [h],5-8,59147,DB00811,Ribavirin
,15703363,renal clearance,The renal clearance was low for both viramidine (5-8 L/h) and ribavirin (4-7 L/h).,"Ascending multiple-dose pharmacokinetics of viramidine, a prodrug of ribavirin, in adult subjects with compensated hepatitis C infection. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15703363/),[l] / [h],4-7,59148,DB00811,Ribavirin
,15703363,accumulation factor,Significant accumulation of viramidine was noted in red blood cells (accumulation factor [R] = 5-8) but not in plasma (R = 2).,"Ascending multiple-dose pharmacokinetics of viramidine, a prodrug of ribavirin, in adult subjects with compensated hepatitis C infection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15703363/),,5-8,59149,DB00811,Ribavirin
,26363369,flow rate,"The analytes and the internal standard (midazolam) were separated on an Acquity UPLC BEH C18 chromatography column (2.1mm×50mm, 1.7μm) using gradient elution with a mobile phase of acetonitrile and 0.1% formic acid in water at a flow rate of 0.4mL/min.","Evaluation of a rapid method for the simultaneous quantification of ribavirin, sofosbuvir and its metabolite in rat plasma by UPLC-MS/MS. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26363369/),[ml] / [min],0.4,65242,DB00811,Ribavirin
,26363369,m/,"The detection was performed on a triple quadrupole tandem mass spectrometer by multiple reaction monitoring (MRM) mode to monitor the precursor-to-product ion transitions of m/z 245.1→113.1 for ribavirin, m/z 530.3→243.1 for sofosbuvir, m/z 261.5→113.1 for GS-331007 and m/z 326.2→291.1 for midazolam (IS) using a positive electrospray ionization interface.","Evaluation of a rapid method for the simultaneous quantification of ribavirin, sofosbuvir and its metabolite in rat plasma by UPLC-MS/MS. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26363369/),,261.5,65243,DB00811,Ribavirin
,26363369,Total time,Total time for each chromatograph was 3.0min.,"Evaluation of a rapid method for the simultaneous quantification of ribavirin, sofosbuvir and its metabolite in rat plasma by UPLC-MS/MS. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26363369/),min,3.0,65244,DB00811,Ribavirin
,10622562,half-life,Calculations revealed a minimum virus production and clearance per day in patients with chronic hepatitis C of approximately 10(10)-10(12) virions per day and an in vivo half-life of the virus in the order of a few hours.,Clinical implications of hepatitis C viral kinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10622562/),h,few,65465,DB00811,Ribavirin
,29735803,area under the-concentration time curve (AUClast),"The simeprevir area under the-concentration time curve (AUClast) and Ctrough were 9.42 h.mg/L and 0.046 mg/L, respectively.",The Observed Effect of Gastric Bypass Surgery on Direct-acting Antiviral Treatment: a Case Report. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29735803/),[h·mg] / [l],9.42,68132,DB00811,Ribavirin
,29735803,Ctrough,"The simeprevir area under the-concentration time curve (AUClast) and Ctrough were 9.42 h.mg/L and 0.046 mg/L, respectively.",The Observed Effect of Gastric Bypass Surgery on Direct-acting Antiviral Treatment: a Case Report. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29735803/),[mg] / [l],0.046,68133,DB00811,Ribavirin
,29735803,Ctrough,The increased dose of simeprevir was well tolerated and Ctrough was 0.532 mg/L. Sofosbuvir AUClast and Ctrough were 0.63 h.mg/L and 0.0013 mg/L. GS-331007 AUClast and Ctrough were 21.02 h.mg/L and 0.35 mg/L. Ribavirin Ctrough was 2.5 mg/L.,The Observed Effect of Gastric Bypass Surgery on Direct-acting Antiviral Treatment: a Case Report. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29735803/),[mg] / [l],0.532,68134,DB00811,Ribavirin
,29735803,AUClast,The increased dose of simeprevir was well tolerated and Ctrough was 0.532 mg/L. Sofosbuvir AUClast and Ctrough were 0.63 h.mg/L and 0.0013 mg/L. GS-331007 AUClast and Ctrough were 21.02 h.mg/L and 0.35 mg/L. Ribavirin Ctrough was 2.5 mg/L.,The Observed Effect of Gastric Bypass Surgery on Direct-acting Antiviral Treatment: a Case Report. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29735803/),[h·mg] / [l],0.63,68135,DB00811,Ribavirin
,29735803,Ctrough,The increased dose of simeprevir was well tolerated and Ctrough was 0.532 mg/L. Sofosbuvir AUClast and Ctrough were 0.63 h.mg/L and 0.0013 mg/L. GS-331007 AUClast and Ctrough were 21.02 h.mg/L and 0.35 mg/L. Ribavirin Ctrough was 2.5 mg/L.,The Observed Effect of Gastric Bypass Surgery on Direct-acting Antiviral Treatment: a Case Report. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29735803/),[mg] / [l],0.0013,68136,DB00811,Ribavirin
,29735803,AUClast,The increased dose of simeprevir was well tolerated and Ctrough was 0.532 mg/L. Sofosbuvir AUClast and Ctrough were 0.63 h.mg/L and 0.0013 mg/L. GS-331007 AUClast and Ctrough were 21.02 h.mg/L and 0.35 mg/L. Ribavirin Ctrough was 2.5 mg/L.,The Observed Effect of Gastric Bypass Surgery on Direct-acting Antiviral Treatment: a Case Report. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29735803/),[h·mg] / [l],21.02,68137,DB00811,Ribavirin
,29735803,Ctrough,The increased dose of simeprevir was well tolerated and Ctrough was 0.532 mg/L. Sofosbuvir AUClast and Ctrough were 0.63 h.mg/L and 0.0013 mg/L. GS-331007 AUClast and Ctrough were 21.02 h.mg/L and 0.35 mg/L. Ribavirin Ctrough was 2.5 mg/L.,The Observed Effect of Gastric Bypass Surgery on Direct-acting Antiviral Treatment: a Case Report. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29735803/),[mg] / [l],0.35,68138,DB00811,Ribavirin
,29735803,Ctrough,The increased dose of simeprevir was well tolerated and Ctrough was 0.532 mg/L. Sofosbuvir AUClast and Ctrough were 0.63 h.mg/L and 0.0013 mg/L. GS-331007 AUClast and Ctrough were 21.02 h.mg/L and 0.35 mg/L. Ribavirin Ctrough was 2.5 mg/L.,The Observed Effect of Gastric Bypass Surgery on Direct-acting Antiviral Treatment: a Case Report. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29735803/),[mg] / [l],2.5,68139,DB00811,Ribavirin
,14695034,bioavailability,"Both methods were similar in determining the mean +/- SD bioavailability (51.8 +/- 21.8% by the two-stage method vs 54.8 +/- 16.4% by nonparametric modeling, p=0.79).",Comparative pharmacokinetic analysis by standard two-stage method versus nonparametric population modeling. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14695034/),%,51.8,69048,DB00811,Ribavirin
,14695034,bioavailability,"Both methods were similar in determining the mean +/- SD bioavailability (51.8 +/- 21.8% by the two-stage method vs 54.8 +/- 16.4% by nonparametric modeling, p=0.79).",Comparative pharmacokinetic analysis by standard two-stage method versus nonparametric population modeling. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14695034/),%,54.8,69049,DB00811,Ribavirin
,19523011,C(max),"In the 180 microg week(-1) group mean +/- SD steady-state (week 12) estimates of AUC(0-168) (ng h(-1) ml(-1)), C(max) (ng ml(-1)) and CL/F (l h(-1)) were 2154 +/- 919, 13.8 +/- 6.7 and 0.102 +/- 0.051, respectively.",Pharmacokinetics and response of obese patients with chronic hepatitis C treated with different doses of PEG-IFN alpha-2a (40KD) (PEGASYS). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19523011/),[l] / [h],2154,69448,DB00811,Ribavirin
,19523011,C(max),"In the 180 microg week(-1) group mean +/- SD steady-state (week 12) estimates of AUC(0-168) (ng h(-1) ml(-1)), C(max) (ng ml(-1)) and CL/F (l h(-1)) were 2154 +/- 919, 13.8 +/- 6.7 and 0.102 +/- 0.051, respectively.",Pharmacokinetics and response of obese patients with chronic hepatitis C treated with different doses of PEG-IFN alpha-2a (40KD) (PEGASYS). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19523011/),,13.8,69449,DB00811,Ribavirin
,19523011,CL/F,"In the 180 microg week(-1) group mean +/- SD steady-state (week 12) estimates of AUC(0-168) (ng h(-1) ml(-1)), C(max) (ng ml(-1)) and CL/F (l h(-1)) were 2154 +/- 919, 13.8 +/- 6.7 and 0.102 +/- 0.051, respectively.",Pharmacokinetics and response of obese patients with chronic hepatitis C treated with different doses of PEG-IFN alpha-2a (40KD) (PEGASYS). ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19523011/),[l] / [h],2154,69450,DB00811,Ribavirin
,19523011,CL/F,"In the 180 microg week(-1) group mean +/- SD steady-state (week 12) estimates of AUC(0-168) (ng h(-1) ml(-1)), C(max) (ng ml(-1)) and CL/F (l h(-1)) were 2154 +/- 919, 13.8 +/- 6.7 and 0.102 +/- 0.051, respectively.",Pharmacokinetics and response of obese patients with chronic hepatitis C treated with different doses of PEG-IFN alpha-2a (40KD) (PEGASYS). ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19523011/),,13.8,69451,DB00811,Ribavirin
,19523011,CL/F,"In the 180 microg week(-1) group mean +/- SD steady-state (week 12) estimates of AUC(0-168) (ng h(-1) ml(-1)), C(max) (ng ml(-1)) and CL/F (l h(-1)) were 2154 +/- 919, 13.8 +/- 6.7 and 0.102 +/- 0.051, respectively.",Pharmacokinetics and response of obese patients with chronic hepatitis C treated with different doses of PEG-IFN alpha-2a (40KD) (PEGASYS). ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19523011/),,0.102,69452,DB00811,Ribavirin
,19523011,C(trough),The mean (range) C(trough) (ng ml(-1)) was 11.2 (4.4-18.5) in the 180 microg week(-1) group and 16.1 (0.4-44.2) in the 270 microg week(-1) group.,Pharmacokinetics and response of obese patients with chronic hepatitis C treated with different doses of PEG-IFN alpha-2a (40KD) (PEGASYS). ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19523011/),[ng] / [ml],11.2,69453,DB00811,Ribavirin
,19523011,C(trough),The mean (range) C(trough) (ng ml(-1)) was 11.2 (4.4-18.5) in the 180 microg week(-1) group and 16.1 (0.4-44.2) in the 270 microg week(-1) group.,Pharmacokinetics and response of obese patients with chronic hepatitis C treated with different doses of PEG-IFN alpha-2a (40KD) (PEGASYS). ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19523011/),[ng] / [ml],16.1,69454,DB00811,Ribavirin
,25971261,concentrations,Average day 14 RBV-MP concentrations were higher in subjects with haemoglobin nadir <10 g/dL relative to patients with haemoglobin nadir ≥10 g/dL (6.54 versus 4.48 pmol/10(6) cells; P = 0.02).,Serum and cellular ribavirin pharmacokinetic and concentration-effect analysis in HCV patients receiving sofosbuvir plus ribavirin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25971261/),[pM] / [10(6],6.54,70297,DB00811,Ribavirin
,25971261,concentrations,Average day 14 RBV-MP concentrations were higher in subjects with haemoglobin nadir <10 g/dL relative to patients with haemoglobin nadir ≥10 g/dL (6.54 versus 4.48 pmol/10(6) cells; P = 0.02).,Serum and cellular ribavirin pharmacokinetic and concentration-effect analysis in HCV patients receiving sofosbuvir plus ribavirin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25971261/),[pM] / [10(6],4.48,70298,DB00811,Ribavirin
,25971261,average,"Additionally, day 14 RBV-MP average concentrations trended towards being higher in subjects that achieved sustained virological response (SVR) as compared with patients who relapsed (4.97 versus 4.09 pmol/10(6) cells; P = 0.07).",Serum and cellular ribavirin pharmacokinetic and concentration-effect analysis in HCV patients receiving sofosbuvir plus ribavirin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25971261/),[pM] / [10(6)·cells],4.97,70299,DB00811,Ribavirin
,25971261,average,"Additionally, day 14 RBV-MP average concentrations trended towards being higher in subjects that achieved sustained virological response (SVR) as compared with patients who relapsed (4.97 versus 4.09 pmol/10(6) cells; P = 0.07).",Serum and cellular ribavirin pharmacokinetic and concentration-effect analysis in HCV patients receiving sofosbuvir plus ribavirin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25971261/),[pM] / [10(6)·cells],4.09,70300,DB00811,Ribavirin
,25971261,concentrations,"Additionally, day 14 RBV-MP average concentrations trended towards being higher in subjects that achieved sustained virological response (SVR) as compared with patients who relapsed (4.97 versus 4.09 pmol/10(6) cells; P = 0.07).",Serum and cellular ribavirin pharmacokinetic and concentration-effect analysis in HCV patients receiving sofosbuvir plus ribavirin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25971261/),[pM] / [10(6)·cells],4.97,70301,DB00811,Ribavirin
,25971261,concentrations,"Additionally, day 14 RBV-MP average concentrations trended towards being higher in subjects that achieved sustained virological response (SVR) as compared with patients who relapsed (4.97 versus 4.09 pmol/10(6) cells; P = 0.07).",Serum and cellular ribavirin pharmacokinetic and concentration-effect analysis in HCV patients receiving sofosbuvir plus ribavirin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25971261/),[pM] / [10(6)·cells],4.09,70302,DB00811,Ribavirin
,31303600,concentration,Average day 10 sofosbuvir metabolite BM 331007 concentration was higher in patients having haemoglobin nadir value <10 g/dl compared to the patients having heamoglobin nadir value >10 g/dl (5.34 versus 4.87 pmol/106 cells; p=0.03).,Pharmacokinetics profile of serum and cellular Sofosbuvir along with its concentration effect analysis in HCV patients receiving Sofosbuvir and Ribavirin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31303600/),[pM] / [106·cells],5.34,70421,DB00811,Ribavirin
,31303600,concentration,Average day 10 sofosbuvir metabolite BM 331007 concentration was higher in patients having haemoglobin nadir value <10 g/dl compared to the patients having heamoglobin nadir value >10 g/dl (5.34 versus 4.87 pmol/106 cells; p=0.03).,Pharmacokinetics profile of serum and cellular Sofosbuvir along with its concentration effect analysis in HCV patients receiving Sofosbuvir and Ribavirin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31303600/),[pM] / [106·cells],4.87,70422,DB00811,Ribavirin
,31303600,concentration,The average concentration trends of GS331007 at day 10 was towards being higher in the patients achieved sustained virologic response (SVR) as compare to the patients relapsed (5.19 versus 4.86 pmol/106 cells; p=0.05).,Pharmacokinetics profile of serum and cellular Sofosbuvir along with its concentration effect analysis in HCV patients receiving Sofosbuvir and Ribavirin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31303600/),,5.19,70423,DB00811,Ribavirin
,31303600,concentration,The average concentration trends of GS331007 at day 10 was towards being higher in the patients achieved sustained virologic response (SVR) as compare to the patients relapsed (5.19 versus 4.86 pmol/106 cells; p=0.05).,Pharmacokinetics profile of serum and cellular Sofosbuvir along with its concentration effect analysis in HCV patients receiving Sofosbuvir and Ribavirin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31303600/),,4.86,70424,DB00811,Ribavirin
,9862245,terminal phase half-lives,The range of mean ribavirin terminal phase half-lives after single doses was 44-49 h.,Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9862245/),h,44-49,72811,DB00811,Ribavirin
,9862245,washout half-lives,"The range of mean washout half-lives after week 6 was 274-298 h, reflecting release of ribavirin from deep compartment stores.",Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9862245/),h,274-298,72812,DB00811,Ribavirin
,9862245,terminal phase half-lives,The range of single and multiple dose IFN terminal phase half-lives was 5-7 h.,Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9862245/),h,5-7,72813,DB00811,Ribavirin
,12451285,half-life,"The volume of distribution was large and proportional to body weight (V = 44.3 x body weight), which resulted in a long half-life (100-500 hours, depending on GFR) and a long time to steady state (3-12 weeks).",Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12451285/),h,100-500,76539,DB00811,Ribavirin
,12451285,time to steady state,"The volume of distribution was large and proportional to body weight (V = 44.3 x body weight), which resulted in a long half-life (100-500 hours, depending on GFR) and a long time to steady state (3-12 weeks).",Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12451285/),weeks,3-12,76540,DB00811,Ribavirin
,6672028,limit of detection,The limit of detection for TCAR in plasma was 40 ng/ml which can be detected by injecting 200 microliter of processed plasma.,Analysis of riboxamide in plasma by high-performance liquid chromatography using automated column switching. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6672028/),[ng] / [ml],40,77720,DB00811,Ribavirin
,6672028,recoveries,"The recoveries from plasma were 100.2 +/- 0.9% and 101.3 +/- 2.3% when spiked at the 10 and 1 microgram/ml levels, respectively.",Analysis of riboxamide in plasma by high-performance liquid chromatography using automated column switching. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6672028/),%,100.2,77721,DB00811,Ribavirin
,6672028,recoveries,"The recoveries from plasma were 100.2 +/- 0.9% and 101.3 +/- 2.3% when spiked at the 10 and 1 microgram/ml levels, respectively.",Analysis of riboxamide in plasma by high-performance liquid chromatography using automated column switching. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6672028/),%,101.3,77722,DB00811,Ribavirin
,24080649,area under the concentration-time curve from 0 to 12 h [AUC0-12]),"Despite this modification, patients with moderate and severe impairment had 12-hour (area under the concentration-time curve from 0 to 12 h [AUC0-12]) values 36% (38,452 ng · h/ml) and 25% (35,101 ng · h/ml) higher, respectively, than those with normal renal function (28,192 ng · h/ml).","Safety, tolerability, and pharmacokinetics of ribavirin in hepatitis C virus-infected patients with various degrees of renal impairment. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24080649/),[h·ng] / [ml],"38,452",81496,DB00811,Ribavirin
,24080649,area under the concentration-time curve from 0 to 12 h [AUC0-12]),"Despite this modification, patients with moderate and severe impairment had 12-hour (area under the concentration-time curve from 0 to 12 h [AUC0-12]) values 36% (38,452 ng · h/ml) and 25% (35,101 ng · h/ml) higher, respectively, than those with normal renal function (28,192 ng · h/ml).","Safety, tolerability, and pharmacokinetics of ribavirin in hepatitis C virus-infected patients with various degrees of renal impairment. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24080649/),[h·ng] / [ml],"35,101",81497,DB00811,Ribavirin
,24080649,area under the concentration-time curve from 0 to 12 h [AUC0-12]),"Despite this modification, patients with moderate and severe impairment had 12-hour (area under the concentration-time curve from 0 to 12 h [AUC0-12]) values 36% (38,452 ng · h/ml) and 25% (35,101 ng · h/ml) higher, respectively, than those with normal renal function (28,192 ng · h/ml).","Safety, tolerability, and pharmacokinetics of ribavirin in hepatitis C virus-infected patients with various degrees of renal impairment. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24080649/),[h·ng] / [ml],"28,192",81498,DB00811,Ribavirin
,24080649,AUC0-12,"Patients with ESRD tolerated a 200-mg daily dose, and AUC0-12 was 20% lower (22,629 ng · h/ml) than in patients with normal renal function.","Safety, tolerability, and pharmacokinetics of ribavirin in hepatitis C virus-infected patients with various degrees of renal impairment. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24080649/),[h·ng] / [ml],"22,629",81499,DB00811,Ribavirin
,8460922,Peak concentrations,"Peak concentrations in plasma of 2.5 and 3.0 microM were reached at 90 min after single oral doses of 6 and 10 mg/kg, respectively.","Safety, tolerance, and pharmacokinetics of systemic ribavirin in children with human immunodeficiency virus infection. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8460922/),μM,2.5,82298,DB00811,Ribavirin
,8460922,Peak concentrations,"Peak concentrations in plasma of 2.5 and 3.0 microM were reached at 90 min after single oral doses of 6 and 10 mg/kg, respectively.","Safety, tolerance, and pharmacokinetics of systemic ribavirin in children with human immunodeficiency virus infection. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8460922/),μM,3.0,82299,DB00811,Ribavirin
,8460922,systemic availability,The mean systemic availability of oral ribavirin was 42.3%.,"Safety, tolerance, and pharmacokinetics of systemic ribavirin in children with human immunodeficiency virus infection. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8460922/),%,42.3,82300,DB00811,Ribavirin
,8460922,trough concentrations,"After 60 days of ribavirin administration, mean trough concentrations in plasma of 2.6 and 4.1 microM were obtained.","Safety, tolerance, and pharmacokinetics of systemic ribavirin in children with human immunodeficiency virus infection. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8460922/),μM,2.6,82301,DB00811,Ribavirin
,8460922,trough concentrations,"After 60 days of ribavirin administration, mean trough concentrations in plasma of 2.6 and 4.1 microM were obtained.","Safety, tolerance, and pharmacokinetics of systemic ribavirin in children with human immunodeficiency virus infection. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8460922/),μM,4.1,82302,DB00811,Ribavirin
,3948303,maximum tolerated dose,"The maximum tolerated dose was 1650 mg/m2 per day, neurological toxicity being the dose-limiting factor.",Phase I and pharmacokinetic study of tiazofurin (NSC 286193) administered by 5-day continuous infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3948303/),[mg] / [m],1650,82597,DB00811,Ribavirin
,3948303,plasma clearance,The plasma clearance was 29.13 (+/- SD 4.05) ml/min per m2.,Phase I and pharmacokinetic study of tiazofurin (NSC 286193) administered by 5-day continuous infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3948303/),[ml] / [m2·min],29.13,82598,DB00811,Ribavirin
,25043197,clearance,"Lambda population pharmacokinetics was described by a one-compartment model with first-order absorption, and 33.0 L per day clearance with 47% interindividual (36% intra-individual) variability.","Derivation of Phase 3 dosing for peginterferon lambda-1a in chronic hepatitis C, Part 1: Modeling optimal treatment duration and sustained virologic response rates. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25043197/),[l] / [d],33.0,83057,DB00811,Ribavirin
,31323954,half-life,The mean plasma HEV half-life was estimated to be 2.0 ± 0.96 days.,Plasma Hepatitis E Virus Kinetics in Solid Organ Transplant Patients Receiving Ribavirin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31323954/),d,2.0,85984,DB00811,Ribavirin
,25911859,trough concentration,Mean peginterferon alfa-2a trough concentration at week 12 was 11.7±4.3 ng/mL for 180 μg and 23.4±11.3 ng/mL for 360 μg.,Induction dosing of peginterferon alfa-2a (40 KD) and/or high-dose ribavirin in genotype 1 CHC patients with difficult-to-treat characteristics: pharmacokinetic and viral kinetic (PK/VK) assessment from PROGRESS. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25911859/),[ng] / [ml],11.7,86055,DB00811,Ribavirin
,25911859,trough concentration,Mean peginterferon alfa-2a trough concentration at week 12 was 11.7±4.3 ng/mL for 180 μg and 23.4±11.3 ng/mL for 360 μg.,Induction dosing of peginterferon alfa-2a (40 KD) and/or high-dose ribavirin in genotype 1 CHC patients with difficult-to-treat characteristics: pharmacokinetic and viral kinetic (PK/VK) assessment from PROGRESS. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25911859/),[ng] / [ml],23.4,86056,DB00811,Ribavirin
,10508023,maximum concentrations,"The mean maximum concentrations of drug in plasma for intravenous and oral ribavirin were 4,187 and 638 ng/ml, respectively.",Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10508023/),[ng] / [ml],"4,",86563,DB00811,Ribavirin
,10508023,maximum concentrations,"The mean maximum concentrations of drug in plasma for intravenous and oral ribavirin were 4,187 and 638 ng/ml, respectively.",Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10508023/),[ng] / [ml],187,86564,DB00811,Ribavirin
,10508023,maximum concentrations,"The mean maximum concentrations of drug in plasma for intravenous and oral ribavirin were 4,187 and 638 ng/ml, respectively.",Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10508023/),[ng] / [ml],638,86565,DB00811,Ribavirin
,10508023,bioavailability,"The mean bioavailability was 51.8% +/- 21.8%, and the mean gamma-phase half-life was 37.0 +/- 14. 2 h.",Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10508023/),%,51.8,86566,DB00811,Ribavirin
,10508023,gamma-phase half-life,"The mean bioavailability was 51.8% +/- 21.8%, and the mean gamma-phase half-life was 37.0 +/- 14. 2 h.",Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10508023/),h,37.0,86567,DB00811,Ribavirin
,10508023,renal clearance,"The mean renal clearance, metabolic clearance, and volume of distribution of the central compartment were 6.94 liters/h, 18.1 liters/h, and 17.8 liters, respectively.",Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10508023/),[l] / [h],6.94,86568,DB00811,Ribavirin
,10508023,metabolic clearance,"The mean renal clearance, metabolic clearance, and volume of distribution of the central compartment were 6.94 liters/h, 18.1 liters/h, and 17.8 liters, respectively.",Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10508023/),[l] / [h],18.1,86569,DB00811,Ribavirin
,10508023,volume of distribution of the central compartment,"The mean renal clearance, metabolic clearance, and volume of distribution of the central compartment were 6.94 liters/h, 18.1 liters/h, and 17.8 liters, respectively.",Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10508023/),l,17.8,86570,DB00811,Ribavirin
,10508023,bioavailability,"The study demonstrated that the mean bioavailability for a 400-mg dose of ribavirin was 52%, which is higher than that previously reported in other investigations.",Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10508023/),%,52,86571,DB00811,Ribavirin
,2380833,peak ribavirin level,The mean (+/- SD) peak ribavirin level after the first dose was 1725 +/- 2179 mumol/L in secretions and 3.8 +/- 2.6 mumol/L in plasma.,"High-dose, short-duration ribavirin aerosol therapy in children with suspected respiratory syncytial virus infection. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2380833/),[μM] / [l],1725,87743,DB00811,Ribavirin
,2380833,peak ribavirin level,The mean (+/- SD) peak ribavirin level after the first dose was 1725 +/- 2179 mumol/L in secretions and 3.8 +/- 2.6 mumol/L in plasma.,"High-dose, short-duration ribavirin aerosol therapy in children with suspected respiratory syncytial virus infection. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2380833/),[μM] / [l],3.8,87744,DB00811,Ribavirin
,2380833,half-life,"Ribavirin in the secretions was rapidly cleared, with a mean (+/- SD), half-life of 1.9 +/- 0.8 hours.","High-dose, short-duration ribavirin aerosol therapy in children with suspected respiratory syncytial virus infection. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2380833/),h,1.9,87745,DB00811,Ribavirin
,2380833,steady state,Plasma ribavirin increased with treatments to reach a steady state of 5 to 10 mumol/L.,"High-dose, short-duration ribavirin aerosol therapy in children with suspected respiratory syncytial virus infection. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2380833/),[μM] / [l],5 to 10,87746,DB00811,Ribavirin
,21098255,maximum concentration in plasma (C(max)),"The maximum concentration in plasma (C(max)) and the area under the concentration-time curve from time zero to infinity (AUC(0-∞)) were 42.8 ± 14.0 ng/ml and 16,414 ± 4,203 ng·h/ml, respectively, for healthy volunteers, while the C(max) and AUC(0-∞) were 49.9 ± 20.9 ng/ml and 18,919 ± 8,008 ng·h/ml, respectively, for ESRD patients.","Single-dose pharmacokinetics, safety, and tolerability of albinterferon alfa-2b in subjects with end-stage renal disease on hemodialysis compared to those in matched healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21098255/),[ng] / [ml],42.8,88953,DB00811,Ribavirin
,21098255,area under the concentration-time curve from time zero to infinity (AUC(0-∞)),"The maximum concentration in plasma (C(max)) and the area under the concentration-time curve from time zero to infinity (AUC(0-∞)) were 42.8 ± 14.0 ng/ml and 16,414 ± 4,203 ng·h/ml, respectively, for healthy volunteers, while the C(max) and AUC(0-∞) were 49.9 ± 20.9 ng/ml and 18,919 ± 8,008 ng·h/ml, respectively, for ESRD patients.","Single-dose pharmacokinetics, safety, and tolerability of albinterferon alfa-2b in subjects with end-stage renal disease on hemodialysis compared to those in matched healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21098255/),[h·ng] / [ml],"16,414",88954,DB00811,Ribavirin
,21098255,C(max),"The maximum concentration in plasma (C(max)) and the area under the concentration-time curve from time zero to infinity (AUC(0-∞)) were 42.8 ± 14.0 ng/ml and 16,414 ± 4,203 ng·h/ml, respectively, for healthy volunteers, while the C(max) and AUC(0-∞) were 49.9 ± 20.9 ng/ml and 18,919 ± 8,008 ng·h/ml, respectively, for ESRD patients.","Single-dose pharmacokinetics, safety, and tolerability of albinterferon alfa-2b in subjects with end-stage renal disease on hemodialysis compared to those in matched healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21098255/),[ng] / [ml],49.9,88955,DB00811,Ribavirin
,21098255,AUC(0-∞),"The maximum concentration in plasma (C(max)) and the area under the concentration-time curve from time zero to infinity (AUC(0-∞)) were 42.8 ± 14.0 ng/ml and 16,414 ± 4,203 ng·h/ml, respectively, for healthy volunteers, while the C(max) and AUC(0-∞) were 49.9 ± 20.9 ng/ml and 18,919 ± 8,008 ng·h/ml, respectively, for ESRD patients.","Single-dose pharmacokinetics, safety, and tolerability of albinterferon alfa-2b in subjects with end-stage renal disease on hemodialysis compared to those in matched healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21098255/),[h·ng] / [ml],"18,919",88956,DB00811,Ribavirin
,19164463,uptake,Ribavirin (2.4 microM) uptake was significantly higher (1044 +/- 255 amol/microg/10 s) into erythrocytes from Ent1(+/+) mice compared with that from Ent1(-/-) mice (76.48 +/- 11.20 amol/microg/10 s).,The role of the equilibrative nucleoside transporter 1 (ENT1) in transport and metabolism of ribavirin by human and wild-type or Ent1-/- mouse erythrocytes. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19164463/),[amol] / [10·s·μg],1044,89368,DB00811,Ribavirin
,19164463,uptake,Ribavirin (2.4 microM) uptake was significantly higher (1044 +/- 255 amol/microg/10 s) into erythrocytes from Ent1(+/+) mice compared with that from Ent1(-/-) mice (76.48 +/- 11.20 amol/microg/10 s).,The role of the equilibrative nucleoside transporter 1 (ENT1) in transport and metabolism of ribavirin by human and wild-type or Ent1-/- mouse erythrocytes. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19164463/),[amol] / [10·s·μg],76.48,89369,DB00811,Ribavirin
,19164463,K(m),Our results showed a saturable (K(m) of 382 +/- 75.1 microM) transport of [(3)H]ribavirin into erythrocytes from Ent1(+/+) mice.,The role of the equilibrative nucleoside transporter 1 (ENT1) in transport and metabolism of ribavirin by human and wild-type or Ent1-/- mouse erythrocytes. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19164463/),μM,382,89370,DB00811,Ribavirin
,16962398,flow rate,The flow rate was 0.4-0.6 ml/min with total cycle time of approximately 7.0 min.,Simultaneous determination of ribavirin and ribavirin base in monkey plasma by high performance liquid chromatography with tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16962398/),[ml] / [min],0.4-0.6,91210,DB00811,Ribavirin
,16962398,total cycle time,The flow rate was 0.4-0.6 ml/min with total cycle time of approximately 7.0 min.,Simultaneous determination of ribavirin and ribavirin base in monkey plasma by high performance liquid chromatography with tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16962398/),min,7.0,91211,DB00811,Ribavirin
,23975236,body surface area normalized apparent clearance,"The mean body surface area normalized apparent clearance of PEG-IFN alfa-2b was 0.56 L/h/m(2), and was similar when evaluated across the pediatric age groups.",Population pharmacokinetics of peginterferon alfa-2b in pediatric patients with chronic hepatitis C. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23975236/),[h·l] / [m(2],0.56,92176,DB00811,Ribavirin
,12493792,Oral absorption,"Oral absorption was 31.3% in rats, 67.3% in dogs and 17.5% in monkeys, and the bioavailability was 29.3% in rats, 51.3% in dogs and 18.4% in monkeys.","Absorption, pharmacokinetics and excretion of levovirin in rats, dogs and cynomolgus monkeys. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12493792/),%,31.3,94012,DB00811,Ribavirin
,12493792,Oral absorption,"Oral absorption was 31.3% in rats, 67.3% in dogs and 17.5% in monkeys, and the bioavailability was 29.3% in rats, 51.3% in dogs and 18.4% in monkeys.","Absorption, pharmacokinetics and excretion of levovirin in rats, dogs and cynomolgus monkeys. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12493792/),%,67.3,94013,DB00811,Ribavirin
,12493792,Oral absorption,"Oral absorption was 31.3% in rats, 67.3% in dogs and 17.5% in monkeys, and the bioavailability was 29.3% in rats, 51.3% in dogs and 18.4% in monkeys.","Absorption, pharmacokinetics and excretion of levovirin in rats, dogs and cynomolgus monkeys. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12493792/),%,17.5,94014,DB00811,Ribavirin
,12493792,bioavailability,"Oral absorption was 31.3% in rats, 67.3% in dogs and 17.5% in monkeys, and the bioavailability was 29.3% in rats, 51.3% in dogs and 18.4% in monkeys.","Absorption, pharmacokinetics and excretion of levovirin in rats, dogs and cynomolgus monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12493792/),%,29.3,94015,DB00811,Ribavirin
,12493792,bioavailability,"Oral absorption was 31.3% in rats, 67.3% in dogs and 17.5% in monkeys, and the bioavailability was 29.3% in rats, 51.3% in dogs and 18.4% in monkeys.","Absorption, pharmacokinetics and excretion of levovirin in rats, dogs and cynomolgus monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12493792/),%,51.3,94016,DB00811,Ribavirin
,12493792,bioavailability,"Oral absorption was 31.3% in rats, 67.3% in dogs and 17.5% in monkeys, and the bioavailability was 29.3% in rats, 51.3% in dogs and 18.4% in monkeys.","Absorption, pharmacokinetics and excretion of levovirin in rats, dogs and cynomolgus monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12493792/),%,18.4,94017,DB00811,Ribavirin
,12493792,elimination half-life (t(1/2)),"After iv administration, the elimination half-life (t(1/2)) was 1.47 h in rats, 3.70 h in dogs and 3.50 h in monkeys.","Absorption, pharmacokinetics and excretion of levovirin in rats, dogs and cynomolgus monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12493792/),h,1.47,94018,DB00811,Ribavirin
,12493792,elimination half-life (t(1/2)),"After iv administration, the elimination half-life (t(1/2)) was 1.47 h in rats, 3.70 h in dogs and 3.50 h in monkeys.","Absorption, pharmacokinetics and excretion of levovirin in rats, dogs and cynomolgus monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12493792/),h,3.70,94019,DB00811,Ribavirin
,12493792,elimination half-life (t(1/2)),"After iv administration, the elimination half-life (t(1/2)) was 1.47 h in rats, 3.70 h in dogs and 3.50 h in monkeys.","Absorption, pharmacokinetics and excretion of levovirin in rats, dogs and cynomolgus monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12493792/),h,3.50,94020,DB00811,Ribavirin
,12493792,total body clearance,"The total body clearance was 8.24, 2.96 and 2.58 mL/min per kg, respectively, in rats, dogs and monkeys and the apparent volume of distribution was 0.79, 0.95 and 0.65 L/kg.","Absorption, pharmacokinetics and excretion of levovirin in rats, dogs and cynomolgus monkeys. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12493792/),[ml] / [kg·min],8.24,94021,DB00811,Ribavirin
,12493792,total body clearance,"The total body clearance was 8.24, 2.96 and 2.58 mL/min per kg, respectively, in rats, dogs and monkeys and the apparent volume of distribution was 0.79, 0.95 and 0.65 L/kg.","Absorption, pharmacokinetics and excretion of levovirin in rats, dogs and cynomolgus monkeys. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12493792/),[ml] / [kg·min],2.96,94022,DB00811,Ribavirin
,12493792,total body clearance,"The total body clearance was 8.24, 2.96 and 2.58 mL/min per kg, respectively, in rats, dogs and monkeys and the apparent volume of distribution was 0.79, 0.95 and 0.65 L/kg.","Absorption, pharmacokinetics and excretion of levovirin in rats, dogs and cynomolgus monkeys. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12493792/),[ml] / [kg·min],2.58,94023,DB00811,Ribavirin
,12493792,apparent volume of distribution,"The total body clearance was 8.24, 2.96 and 2.58 mL/min per kg, respectively, in rats, dogs and monkeys and the apparent volume of distribution was 0.79, 0.95 and 0.65 L/kg.","Absorption, pharmacokinetics and excretion of levovirin in rats, dogs and cynomolgus monkeys. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12493792/),[l] / [kg],0.79,94024,DB00811,Ribavirin
,12493792,apparent volume of distribution,"The total body clearance was 8.24, 2.96 and 2.58 mL/min per kg, respectively, in rats, dogs and monkeys and the apparent volume of distribution was 0.79, 0.95 and 0.65 L/kg.","Absorption, pharmacokinetics and excretion of levovirin in rats, dogs and cynomolgus monkeys. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12493792/),[l] / [kg],0.95,94025,DB00811,Ribavirin
,12493792,apparent volume of distribution,"The total body clearance was 8.24, 2.96 and 2.58 mL/min per kg, respectively, in rats, dogs and monkeys and the apparent volume of distribution was 0.79, 0.95 and 0.65 L/kg.","Absorption, pharmacokinetics and excretion of levovirin in rats, dogs and cynomolgus monkeys. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12493792/),[l] / [kg],0.65,94026,DB00811,Ribavirin
,12493792,Excretion,"Excretion of total radioactivity in urine after oral dosing accounted for 15.4% of the administered dose in rats, 49.9% in dogs and 21.4% in monkeys.","Absorption, pharmacokinetics and excretion of levovirin in rats, dogs and cynomolgus monkeys. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12493792/),,49,94027,DB00811,Ribavirin
,12493792,Excretion,"Excretion of total radioactivity in urine after oral dosing accounted for 15.4% of the administered dose in rats, 49.9% in dogs and 21.4% in monkeys.","Absorption, pharmacokinetics and excretion of levovirin in rats, dogs and cynomolgus monkeys. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12493792/),,21,94028,DB00811,Ribavirin
,18211620,half-life,"High level of erythrocyte ribavirin (1085 microM; mostly as phosphorylated metabolites) with long half-life (15 days) caused severe anaemia, which required several blood transfusions for 2 weeks after the cessation of the ribavirin treatment.",Blood ribavirin concentration in high-dose ribavirin for adenovirus-induced haemorrhagic cystitis - a case report. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18211620/),d,15,101142,DB00811,Ribavirin
,1680594,terminal plasma half-life (t1/2),"After a single 400 mg intravenous infusion, mean terminal plasma half-life (t1/2) was 27.1 hours, mean volume of distribution was 802 L, and mean total plasma clearance was 26.1 L/hr.",Pharmacokinetics and long-term tolerance to ribavirin in asymptomatic patients infected with human immunodeficiency virus. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1680594/),h,27.1,102853,DB00811,Ribavirin
,1680594,volume of distribution,"After a single 400 mg intravenous infusion, mean terminal plasma half-life (t1/2) was 27.1 hours, mean volume of distribution was 802 L, and mean total plasma clearance was 26.1 L/hr.",Pharmacokinetics and long-term tolerance to ribavirin in asymptomatic patients infected with human immunodeficiency virus. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1680594/),l,802,102854,DB00811,Ribavirin
,1680594,total plasma clearance,"After a single 400 mg intravenous infusion, mean terminal plasma half-life (t1/2) was 27.1 hours, mean volume of distribution was 802 L, and mean total plasma clearance was 26.1 L/hr.",Pharmacokinetics and long-term tolerance to ribavirin in asymptomatic patients infected with human immunodeficiency virus. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1680594/),[l] / [h],26.1,102855,DB00811,Ribavirin
,1680594,Oral bioavailability,Oral bioavailability was 44.6%.,Pharmacokinetics and long-term tolerance to ribavirin in asymptomatic patients infected with human immunodeficiency virus. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1680594/),%,44.6,102856,DB00811,Ribavirin
,1680594,terminal t1/2 (washout),The terminal t1/2 (washout) after 16 weeks greatly exceeded the t1/2 observed after a single oral dose (151 versus 29.6 hours).,Pharmacokinetics and long-term tolerance to ribavirin in asymptomatic patients infected with human immunodeficiency virus. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1680594/),h,151,102857,DB00811,Ribavirin
,1680594,terminal t1/2 (washout),The terminal t1/2 (washout) after 16 weeks greatly exceeded the t1/2 observed after a single oral dose (151 versus 29.6 hours).,Pharmacokinetics and long-term tolerance to ribavirin in asymptomatic patients infected with human immunodeficiency virus. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1680594/),h,29.6,102858,DB00811,Ribavirin
,1680594,t1/2,The terminal t1/2 (washout) after 16 weeks greatly exceeded the t1/2 observed after a single oral dose (151 versus 29.6 hours).,Pharmacokinetics and long-term tolerance to ribavirin in asymptomatic patients infected with human immunodeficiency virus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1680594/),h,151,102859,DB00811,Ribavirin
,1680594,t1/2,The terminal t1/2 (washout) after 16 weeks greatly exceeded the t1/2 observed after a single oral dose (151 versus 29.6 hours).,Pharmacokinetics and long-term tolerance to ribavirin in asymptomatic patients infected with human immunodeficiency virus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1680594/),h,29.6,102860,DB00811,Ribavirin
,17501760,t(1/2),"C(max) of PEG-IFN occurred 12-48 h after the initial administration, with t(1/2) and C(min) being 49 h and 190 pg/mL, respectively.",Pharmacokinetics and enhanced PKR response in patients with chronic hepatitis C treated with pegylated interferon alpha-2b and ribavirin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17501760/),h,49,105350,DB00811,Ribavirin
,17501760,C(min),"C(max) of PEG-IFN occurred 12-48 h after the initial administration, with t(1/2) and C(min) being 49 h and 190 pg/mL, respectively.",Pharmacokinetics and enhanced PKR response in patients with chronic hepatitis C treated with pegylated interferon alpha-2b and ribavirin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17501760/),[pg] / [ml],190,105351,DB00811,Ribavirin
,18435468,AUC(0-12h),"Patients with a SVR had a significantly higher D0 AUC(0-12h) (3695 [1571-6916] versus 2937 [1266-4913] microg/hour/L, P = 0.03) and D0 AUC(0-4h) (2010 [615-3175] versus 1340 [622-2246] microg/hour/L, P = 0.03).",Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18435468/),[μg] / [h·l],3695,109978,DB00811,Ribavirin
,18435468,AUC(0-12h),"Patients with a SVR had a significantly higher D0 AUC(0-12h) (3695 [1571-6916] versus 2937 [1266-4913] microg/hour/L, P = 0.03) and D0 AUC(0-4h) (2010 [615-3175] versus 1340 [622-2246] microg/hour/L, P = 0.03).",Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18435468/),[μg] / [h·l],2937,109979,DB00811,Ribavirin
,18435468,AUC(0-4h),"Patients with a SVR had a significantly higher D0 AUC(0-12h) (3695 [1571-6916] versus 2937 [1266-4913] microg/hour/L, P = 0.03) and D0 AUC(0-4h) (2010 [615-3175] versus 1340 [622-2246] microg/hour/L, P = 0.03).",Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18435468/),[μg] / [h·l],2010,109980,DB00811,Ribavirin
,18435468,AUC(0-4h),"Patients with a SVR had a significantly higher D0 AUC(0-12h) (3695 [1571-6916] versus 2937 [1266-4913] microg/hour/L, P = 0.03) and D0 AUC(0-4h) (2010 [615-3175] versus 1340 [622-2246] microg/hour/L, P = 0.03).",Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18435468/),[μg] / [h·l],1340,109981,DB00811,Ribavirin
,18435468,AUCs,"Patients with D0 AUCs above the cut-off values defined by receiver operating characteristic curves (3014 microg/hour/L and 1755 microg/hour/L for AUC(0-12h) and AUC(0-4h), respectively) had a significantly better chance of achieving an SVR than patients with AUCs under the thresholds (odds ratio = 16.0, 95% confidence interval 1.54-166.6, P = 0.02 and odds ratio = 8.9, 95% confidence interval, 1.4-56.6; P = 0.02).",Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18435468/),[μg] / [h·l],3014,109982,DB00811,Ribavirin
,18435468,AUCs,"Patients with D0 AUCs above the cut-off values defined by receiver operating characteristic curves (3014 microg/hour/L and 1755 microg/hour/L for AUC(0-12h) and AUC(0-4h), respectively) had a significantly better chance of achieving an SVR than patients with AUCs under the thresholds (odds ratio = 16.0, 95% confidence interval 1.54-166.6, P = 0.02 and odds ratio = 8.9, 95% confidence interval, 1.4-56.6; P = 0.02).",Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18435468/),[μg] / [h·l],1755,109983,DB00811,Ribavirin
,18435468,AUC(0-12h),"Patients with D0 AUCs above the cut-off values defined by receiver operating characteristic curves (3014 microg/hour/L and 1755 microg/hour/L for AUC(0-12h) and AUC(0-4h), respectively) had a significantly better chance of achieving an SVR than patients with AUCs under the thresholds (odds ratio = 16.0, 95% confidence interval 1.54-166.6, P = 0.02 and odds ratio = 8.9, 95% confidence interval, 1.4-56.6; P = 0.02).",Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18435468/),[μg] / [h·l],3014,109984,DB00811,Ribavirin
,18435468,AUC(0-12h),"Patients with D0 AUCs above the cut-off values defined by receiver operating characteristic curves (3014 microg/hour/L and 1755 microg/hour/L for AUC(0-12h) and AUC(0-4h), respectively) had a significantly better chance of achieving an SVR than patients with AUCs under the thresholds (odds ratio = 16.0, 95% confidence interval 1.54-166.6, P = 0.02 and odds ratio = 8.9, 95% confidence interval, 1.4-56.6; P = 0.02).",Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18435468/),[μg] / [h·l],1755,109985,DB00811,Ribavirin
,18435468,AUC(0-4h),"Patients with D0 AUCs above the cut-off values defined by receiver operating characteristic curves (3014 microg/hour/L and 1755 microg/hour/L for AUC(0-12h) and AUC(0-4h), respectively) had a significantly better chance of achieving an SVR than patients with AUCs under the thresholds (odds ratio = 16.0, 95% confidence interval 1.54-166.6, P = 0.02 and odds ratio = 8.9, 95% confidence interval, 1.4-56.6; P = 0.02).",Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18435468/),[μg] / [h·l],1755,109986,DB00811,Ribavirin
,18435468,AUC(0-4h),We propose a minimum AUC(0-4h) threshold of 1755 microg/hour/L at D0 as a target for ribavirin dose adjustment.,Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18435468/),[μg] / [h·l],1755,109987,DB00811,Ribavirin
,6144481,IC50,"In all cases, the mean concentration of unchanged drug prevailing during this terminal phase was well within the cytotoxic range (IC50 vs. P388 cells is 2 microM in vitro).","The disposition and metabolism of tiazofurin in rodents, rabbits, and dogs. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6144481/),μM,2,114349,DB00811,Ribavirin
,32920958,BAL concentrations,"In patient 2, iRTP BAL concentrations were 103 pmol/106 cells after 5 days of oral followed by 5 days of inhaled ribavirin.",Ribavirin and cellular ribavirin-triphosphate concentrations in blood and bronchoalveolar lavage fluid in two lung transplant patients with respiratory syncytial virus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32920958/),[pM] / [106·cells],103,120211,DB00811,Ribavirin
,12878505,oral absorption,"The levels of oral absorption and bioavailabilities were 61.7 and 9.91%, respectively, in rats and 43.9 and 13.6%, respectively, in monkeys.",Pharmacokinetics and metabolism of [14C]viramidine in rats and cynomolgus monkeys. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878505/),%,61.7,121082,DB00811,Ribavirin
,12878505,oral absorption,"The levels of oral absorption and bioavailabilities were 61.7 and 9.91%, respectively, in rats and 43.9 and 13.6%, respectively, in monkeys.",Pharmacokinetics and metabolism of [14C]viramidine in rats and cynomolgus monkeys. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878505/),%,43.9,121083,DB00811,Ribavirin
,12878505,bioavailabilities,"The levels of oral absorption and bioavailabilities were 61.7 and 9.91%, respectively, in rats and 43.9 and 13.6%, respectively, in monkeys.",Pharmacokinetics and metabolism of [14C]viramidine in rats and cynomolgus monkeys. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878505/),%,9.91,121084,DB00811,Ribavirin
,12878505,bioavailabilities,"The levels of oral absorption and bioavailabilities were 61.7 and 9.91%, respectively, in rats and 43.9 and 13.6%, respectively, in monkeys.",Pharmacokinetics and metabolism of [14C]viramidine in rats and cynomolgus monkeys. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878505/),%,43.9,121085,DB00811,Ribavirin
,12878505,bioavailabilities,"The levels of oral absorption and bioavailabilities were 61.7 and 9.91%, respectively, in rats and 43.9 and 13.6%, respectively, in monkeys.",Pharmacokinetics and metabolism of [14C]viramidine in rats and cynomolgus monkeys. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878505/),%,13.6,121086,DB00811,Ribavirin
,12878505,elimination half-lives,"Following i.v. administration, the elimination half-lives were 2.7 h in rats and 28.9 h in monkeys.",Pharmacokinetics and metabolism of [14C]viramidine in rats and cynomolgus monkeys. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878505/),h,2.7,121087,DB00811,Ribavirin
,12878505,elimination half-lives,"Following i.v. administration, the elimination half-lives were 2.7 h in rats and 28.9 h in monkeys.",Pharmacokinetics and metabolism of [14C]viramidine in rats and cynomolgus monkeys. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878505/),h,28.9,121088,DB00811,Ribavirin
,12878505,Total body clearances,Total body clearances were 14.0 liters/h/kg in rats and 1.23 liters/h/kg in monkeys; the apparent volumes of distribution were 15.6 liters/kg in rats and 18.6 liters/kg in monkeys.,Pharmacokinetics and metabolism of [14C]viramidine in rats and cynomolgus monkeys. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878505/),[l] / [h·kg],14.0,121089,DB00811,Ribavirin
,12878505,Total body clearances,Total body clearances were 14.0 liters/h/kg in rats and 1.23 liters/h/kg in monkeys; the apparent volumes of distribution were 15.6 liters/kg in rats and 18.6 liters/kg in monkeys.,Pharmacokinetics and metabolism of [14C]viramidine in rats and cynomolgus monkeys. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878505/),[l] / [h·kg],1.23,121090,DB00811,Ribavirin
,12878505,apparent volumes of distribution,Total body clearances were 14.0 liters/h/kg in rats and 1.23 liters/h/kg in monkeys; the apparent volumes of distribution were 15.6 liters/kg in rats and 18.6 liters/kg in monkeys.,Pharmacokinetics and metabolism of [14C]viramidine in rats and cynomolgus monkeys. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878505/),[l] / [kg],15.6,121091,DB00811,Ribavirin
,12878505,apparent volumes of distribution,Total body clearances were 14.0 liters/h/kg in rats and 1.23 liters/h/kg in monkeys; the apparent volumes of distribution were 15.6 liters/kg in rats and 18.6 liters/kg in monkeys.,Pharmacokinetics and metabolism of [14C]viramidine in rats and cynomolgus monkeys. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878505/),[l] / [kg],18.6,121092,DB00811,Ribavirin
,12680884,Cmax,"Increased Cmax and accumulation index of AUC(0,12 h) (median 10.5; 95% CI 6.4, 12.4), and prolonged washout half-life after multiple dosing reflected accumulation and slow clearance of ribavirin from the tissue compartments.",Pharmacokinetics of ribavirin in combined interferon-alpha 2b and ribavirin therapy for chronic hepatitis C virus infection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12680884/),,10.5,125259,DB00811,Ribavirin
,27919899,50% effective concentration (EC50),All darunavir trough concentrations (Ctrough) associated with an HIV-1 RNA level of >40 copies/ml were above the darunavir 50% effective concentration (EC50) of 550 ng/ml for resistant virus.,Pharmacokinetic Evaluation of Darunavir Administered Once or Twice Daily in Combination with Ritonavir or the Three-Direct-Acting Antiviral Regimen of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults Coinfected with Hepatitis C and Human Immunodeficiency Viruses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27919899/),[ng] / [ml],550,126677,DB00811,Ribavirin
below,27919899,Ctrough,Episodes of intermittent HIV-1 viremia were infrequent and were not associated with darunavir Ctrough values below 550 ng/ml.,Pharmacokinetic Evaluation of Darunavir Administered Once or Twice Daily in Combination with Ritonavir or the Three-Direct-Acting Antiviral Regimen of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults Coinfected with Hepatitis C and Human Immunodeficiency Viruses. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27919899/),[ng] / [ml],550,126678,DB00811,Ribavirin
,11034261,CL/F,Population mean CL/F estimates were 17.9 L/h (female) and 21.5 L/h (male) assuming an age of 40 years and body weight of 70 kg.,Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11034261/),[l] / [h],17.9,130818,DB00811,Ribavirin
,11034261,CL/F,Population mean CL/F estimates were 17.9 L/h (female) and 21.5 L/h (male) assuming an age of 40 years and body weight of 70 kg.,Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11034261/),[l] / [h],21.5,130819,DB00811,Ribavirin
,29439971,total hepatic metabolite concentrations,"Median total hepatic metabolite concentrations (the sum of nucleoside and mono-, di-, and triphosphates) were 77.1 μM for sofosbuvir and 361 μM for ribavirin in patients on therapy at the time of transplantation.",Sofosbuvir and Ribavirin Liver Pharmacokinetics in Patients Infected with Hepatitis C Virus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29439971/),μM,77.1,130993,DB00811,Ribavirin
,29439971,total hepatic metabolite concentrations,"Median total hepatic metabolite concentrations (the sum of nucleoside and mono-, di-, and triphosphates) were 77.1 μM for sofosbuvir and 361 μM for ribavirin in patients on therapy at the time of transplantation.",Sofosbuvir and Ribavirin Liver Pharmacokinetics in Patients Infected with Hepatitis C Virus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29439971/),μM,361,130994,DB00811,Ribavirin
,17894655,Sustained virological response rates,"Sustained virological response rates were 38%, 30% and 18%, in the 360, 270 and 180 microg/week groups, respectively (relapse rates: 25%, 50% and 64%, respectively).",Clinical trial: pharmacodynamics and pharmacokinetics of re-treatment with fixed-dose induction of peginterferon alpha-2a in hepatitis C virus genotype 1 true non-responder patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17894655/),%,38,145815,DB00811,Ribavirin
,17894655,Sustained virological response rates,"Sustained virological response rates were 38%, 30% and 18%, in the 360, 270 and 180 microg/week groups, respectively (relapse rates: 25%, 50% and 64%, respectively).",Clinical trial: pharmacodynamics and pharmacokinetics of re-treatment with fixed-dose induction of peginterferon alpha-2a in hepatitis C virus genotype 1 true non-responder patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17894655/),%,30,145816,DB00811,Ribavirin
,17894655,Sustained virological response rates,"Sustained virological response rates were 38%, 30% and 18%, in the 360, 270 and 180 microg/week groups, respectively (relapse rates: 25%, 50% and 64%, respectively).",Clinical trial: pharmacodynamics and pharmacokinetics of re-treatment with fixed-dose induction of peginterferon alpha-2a in hepatitis C virus genotype 1 true non-responder patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17894655/),%,18,145817,DB00811,Ribavirin
,17894655,relapse rates,"Sustained virological response rates were 38%, 30% and 18%, in the 360, 270 and 180 microg/week groups, respectively (relapse rates: 25%, 50% and 64%, respectively).",Clinical trial: pharmacodynamics and pharmacokinetics of re-treatment with fixed-dose induction of peginterferon alpha-2a in hepatitis C virus genotype 1 true non-responder patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17894655/),%,25,145818,DB00811,Ribavirin
,17894655,relapse rates,"Sustained virological response rates were 38%, 30% and 18%, in the 360, 270 and 180 microg/week groups, respectively (relapse rates: 25%, 50% and 64%, respectively).",Clinical trial: pharmacodynamics and pharmacokinetics of re-treatment with fixed-dose induction of peginterferon alpha-2a in hepatitis C virus genotype 1 true non-responder patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17894655/),%,50,145819,DB00811,Ribavirin
,17894655,relapse rates,"Sustained virological response rates were 38%, 30% and 18%, in the 360, 270 and 180 microg/week groups, respectively (relapse rates: 25%, 50% and 64%, respectively).",Clinical trial: pharmacodynamics and pharmacokinetics of re-treatment with fixed-dose induction of peginterferon alpha-2a in hepatitis C virus genotype 1 true non-responder patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17894655/),%,64,145820,DB00811,Ribavirin
,20823284,K(i),"It is a highly optimized noncovalent competitive inhibitor of full-length NS3-NS4A proteases of HCV genotypes 1a and 1b with K(i) values of 2.6 and 2.0 nM, respectively.","Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20823284/),nM,2.6,146021,DB00811,Ribavirin
,20823284,K(i),"It is a highly optimized noncovalent competitive inhibitor of full-length NS3-NS4A proteases of HCV genotypes 1a and 1b with K(i) values of 2.6 and 2.0 nM, respectively.","Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20823284/),nM,2.0,146022,DB00811,Ribavirin
,20823284,K(i),"K(i) values of 2 to 230 nM were measured against the NS3-NS4A proteases of HCV genotypes 2 to 6, whereas it was a very weak inhibitor of cathepsin B and showed no measurable inhibition of human leukocyte elastase.","Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20823284/),nM,2 to 230,146023,DB00811,Ribavirin
,20823284,50% effective concentrations (EC(50)s),BI 201335 was also shown to be a potent inhibitor of HCV RNA replication in vitro with 50% effective concentrations (EC(50)s) of 6.5 and 3.1 nM obtained in genotype 1a and 1b replicon assays.,"Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20823284/),nM,6.5,146024,DB00811,Ribavirin
,20823284,50% effective concentrations (EC(50)s),BI 201335 was also shown to be a potent inhibitor of HCV RNA replication in vitro with 50% effective concentrations (EC(50)s) of 6.5 and 3.1 nM obtained in genotype 1a and 1b replicon assays.,"Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20823284/),nM,3.1,146025,DB00811,Ribavirin
,23183434,absorption lag,Pharmacokinetics were best described by a two-compartment model with an 8.4-h absorption lag.,Pegylated interferon fractal pharmacokinetics: individualized dosing for hepatitis C virus infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23183434/),h,8.4,147908,DB00811,Ribavirin
≤,23183434,area under the curve (AUC),"SVR was achieved in 36% of patients; a PEGIFN cumulative 1-week area under the curve (AUC) of ≤0.79 mg · h/liter scored highest in predicting poor response, followed by a weight of ≥93.7 kg.",Pegylated interferon fractal pharmacokinetics: individualized dosing for hepatitis C virus infection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23183434/),[h·mg] / [l],0.79,147909,DB00811,Ribavirin
>,23183434,AUC,"Patients with a PEGIFN AUC of >0.79 mg · h/liter achieved undetectable viral load more rapidly than those with a lower AUC (hazard ratio, 1.63; 95% confidence interval, 1.21 to 2.04).",Pegylated interferon fractal pharmacokinetics: individualized dosing for hepatitis C virus infection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23183434/),[h·mg] / [l],0.79,147910,DB00811,Ribavirin
,8980920,B,"The parameters estimated were as follows: B, 5.90 +/- 1.86 micrograms.h1-s; lambda, 0.607 +/- 0.156 h-s; and s, 0.339 +/- 0.085, respectively.",Weibull function fits to pharmacokinetic data of ribavirin in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8980920/),h1-s·μg,5.90,151682,DB00811,Ribavirin
,8980920,lambda,"The parameters estimated were as follows: B, 5.90 +/- 1.86 micrograms.h1-s; lambda, 0.607 +/- 0.156 h-s; and s, 0.339 +/- 0.085, respectively.",Weibull function fits to pharmacokinetic data of ribavirin in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8980920/),h-s,0.607,151683,DB00811,Ribavirin
,8980920,s,"The parameters estimated were as follows: B, 5.90 +/- 1.86 micrograms.h1-s; lambda, 0.607 +/- 0.156 h-s; and s, 0.339 +/- 0.085, respectively.",Weibull function fits to pharmacokinetic data of ribavirin in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8980920/),,0.339,151684,DB00811,Ribavirin
,4027992,maximally tolerated dose,The maximally tolerated dose was 2200 mg/sq m/day.,Pediatric phase I trial and pharmacokinetic study of tiazofurin (NSC 286193). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4027992/),,220,153280,DB00811,Ribavirin
,4027992,half-lives,"Plasma disappearance was triphasic with half-lives of 9.7 min, 1.6 h, and 5.5 h.",Pediatric phase I trial and pharmacokinetic study of tiazofurin (NSC 286193). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4027992/),min,9.7,153281,DB00811,Ribavirin
,4027992,half-lives,"Plasma disappearance was triphasic with half-lives of 9.7 min, 1.6 h, and 5.5 h.",Pediatric phase I trial and pharmacokinetic study of tiazofurin (NSC 286193). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4027992/),h,1.6,153282,DB00811,Ribavirin
,4027992,half-lives,"Plasma disappearance was triphasic with half-lives of 9.7 min, 1.6 h, and 5.5 h.",Pediatric phase I trial and pharmacokinetic study of tiazofurin (NSC 286193). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4027992/),h,5.5,153283,DB00811,Ribavirin
,4027992,Clearance,"Clearance was dose related, ranging from 120 ml/min/sq m at 550 mg/sq m/day to 70 ml/min/sq m at 3300 mg/sq m/day.",Pediatric phase I trial and pharmacokinetic study of tiazofurin (NSC 286193). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4027992/),[ml] / [m·min·sq],120,153284,DB00811,Ribavirin
,4027992,Clearance,"Clearance was dose related, ranging from 120 ml/min/sq m at 550 mg/sq m/day to 70 ml/min/sq m at 3300 mg/sq m/day.",Pediatric phase I trial and pharmacokinetic study of tiazofurin (NSC 286193). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4027992/),[ml] / [m·min·sq],70,153285,DB00811,Ribavirin
,2334164,Plasma dialysis clearance,Plasma dialysis clearance averaged 93.9 +/- 8.6 ml/min.,Hemodialysis clearance of intravenously administered ribavirin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2334164/),[ml] / [min],93.9,159825,DB00811,Ribavirin
,2334164,maximum amount,The maximum amount of ribavirin removed from the body during one period of hemodialysis was 79.1 mg.,Hemodialysis clearance of intravenously administered ribavirin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2334164/),mg,79.1,159826,DB00811,Ribavirin
,27999010,C trough,"The geometric mean (95% CI) of C trough of rilpivirine and dolutegravir did not change between baseline and week 4 ( P = 0.654 and P = 0.268, respectively), with corresponding overall values of 135 (102-177) and 1357 (970-1897) ng/mL.",Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus-coinfected patients with liver cirrhosis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27999010/),[ng] / [ml],135,167953,DB00811,Ribavirin
,27999010,C trough,"The geometric mean (95% CI) of C trough of rilpivirine and dolutegravir did not change between baseline and week 4 ( P = 0.654 and P = 0.268, respectively), with corresponding overall values of 135 (102-177) and 1357 (970-1897) ng/mL.",Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus-coinfected patients with liver cirrhosis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27999010/),[ng] / [ml],1357,167954,DB00811,Ribavirin
,27999010,C trough,"The overall geometric mean (95% CI) of GS-331007 and simeprevir C trough was 370 (268-512) and 2537 (1569-4101) ng/mL, respectively, without significant variation between weeks 2 and 4 ( P = 0.643 and P = 0.179, respectively).",Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus-coinfected patients with liver cirrhosis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27999010/),[ng] / [ml],370,167955,DB00811,Ribavirin
,27999010,C trough,"The overall geometric mean (95% CI) of GS-331007 and simeprevir C trough was 370 (268-512) and 2537 (1569-4101) ng/mL, respectively, without significant variation between weeks 2 and 4 ( P = 0.643 and P = 0.179, respectively).",Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus-coinfected patients with liver cirrhosis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27999010/),[ng] / [ml],2537,167956,DB00811,Ribavirin
,11443562,serum half-life,"The mean serum half-life was 22.4 days in study 1, which mainly included autologous HSCT recipients, and 10.7 days in study 2, which mainly included allogeneic HSCT recipients.",Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11443562/),d,22.4,172253,DB00811,Ribavirin
,11443562,serum half-life,"The mean serum half-life was 22.4 days in study 1, which mainly included autologous HSCT recipients, and 10.7 days in study 2, which mainly included allogeneic HSCT recipients.",Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11443562/),d,10.7,172254,DB00811,Ribavirin
,24649882,plasma concentrations,"Median (range) telaprevir plasma concentrations of TW 4, 8 and 12 were 3970 (1980-4430) ng/ml and 2520 (1870-8730) ng/ml in patients after OLT and ciclosporin- or tacrolimus-based IS, respectively, as compared to 2790 (1870-3140) in non-OLT patients (P = 0.3).",Telaprevir drug monitoring during antiviral therapy of hepatitis C graft infection after liver transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24649882/),[ng] / [ml],3970,175021,DB00811,Ribavirin
,24649882,plasma concentrations,"Median (range) telaprevir plasma concentrations of TW 4, 8 and 12 were 3970 (1980-4430) ng/ml and 2520 (1870-8730) ng/ml in patients after OLT and ciclosporin- or tacrolimus-based IS, respectively, as compared to 2790 (1870-3140) in non-OLT patients (P = 0.3).",Telaprevir drug monitoring during antiviral therapy of hepatitis C graft infection after liver transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24649882/),[ng] / [ml],2520,175022,DB00811,Ribavirin
,24649882,plasma concentrations,"Median (range) telaprevir plasma concentrations of TW 4, 8 and 12 were 3970 (1980-4430) ng/ml and 2520 (1870-8730) ng/ml in patients after OLT and ciclosporin- or tacrolimus-based IS, respectively, as compared to 2790 (1870-3140) in non-OLT patients (P = 0.3).",Telaprevir drug monitoring during antiviral therapy of hepatitis C graft infection after liver transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24649882/),,2790,175023,DB00811,Ribavirin
,2737800,plasma half-life,"The unchanged drug was confirmed to have a long plasma half-life, ranging from 30.4 to 61.0 h with a total clearance of 20.3 +/- 10.6 1 h-1.","Pharmacokinetics of ribavirin and urinary excretion of the major metabolite 1,2,4-triazole-3-carboxamide in normal volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2737800/),h,30.4 to 61.0,177565,DB00811,Ribavirin
,2737800,total clearance,"The unchanged drug was confirmed to have a long plasma half-life, ranging from 30.4 to 61.0 h with a total clearance of 20.3 +/- 10.6 1 h-1.","Pharmacokinetics of ribavirin and urinary excretion of the major metabolite 1,2,4-triazole-3-carboxamide in normal volunteers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2737800/),[1] / [h],20.3,177566,DB00811,Ribavirin
,2737800,oral bioavailability,"The comparison of oral and i.v. administrations, showed 32.6 +/- 16.7% oral bioavailability.","Pharmacokinetics of ribavirin and urinary excretion of the major metabolite 1,2,4-triazole-3-carboxamide in normal volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2737800/),%,32.6,177567,DB00811,Ribavirin
,19602549,dose-normalized plasma AUC(0-12 h),"After oral administration of three different doses, 0.024, 0.24, and 6.1 mg/kg, we found that the dose-normalized plasma AUC(0-12 h) of ribavirin was 69.7 +/- 12.0, 20.7 +/- 1.5, and 18.3 +/- 2.7 min/l, respectively, in the Ent1(+/+) mice and 18.9 +/- 2.8, 13.0 +/- 0.5, and 12.2 +/- 1.0 min/l, respectively, in the Ent1(-/-) mice.",The role of nucleoside transporters in the erythrocyte disposition and oral absorption of ribavirin in the wild-type and equilibrative nucleoside transporter 1-/- mice. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19602549/),[min] / [l],69.7,179534,DB00811,Ribavirin
,19602549,dose-normalized plasma AUC(0-12 h),"After oral administration of three different doses, 0.024, 0.24, and 6.1 mg/kg, we found that the dose-normalized plasma AUC(0-12 h) of ribavirin was 69.7 +/- 12.0, 20.7 +/- 1.5, and 18.3 +/- 2.7 min/l, respectively, in the Ent1(+/+) mice and 18.9 +/- 2.8, 13.0 +/- 0.5, and 12.2 +/- 1.0 min/l, respectively, in the Ent1(-/-) mice.",The role of nucleoside transporters in the erythrocyte disposition and oral absorption of ribavirin in the wild-type and equilibrative nucleoside transporter 1-/- mice. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19602549/),[min] / [l],20.7,179535,DB00811,Ribavirin
,19602549,dose-normalized plasma AUC(0-12 h),"After oral administration of three different doses, 0.024, 0.24, and 6.1 mg/kg, we found that the dose-normalized plasma AUC(0-12 h) of ribavirin was 69.7 +/- 12.0, 20.7 +/- 1.5, and 18.3 +/- 2.7 min/l, respectively, in the Ent1(+/+) mice and 18.9 +/- 2.8, 13.0 +/- 0.5, and 12.2 +/- 1.0 min/l, respectively, in the Ent1(-/-) mice.",The role of nucleoside transporters in the erythrocyte disposition and oral absorption of ribavirin in the wild-type and equilibrative nucleoside transporter 1-/- mice. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19602549/),[min] / [l],18.3,179536,DB00811,Ribavirin
,19602549,dose-normalized plasma AUC(0-12 h),"After oral administration of three different doses, 0.024, 0.24, and 6.1 mg/kg, we found that the dose-normalized plasma AUC(0-12 h) of ribavirin was 69.7 +/- 12.0, 20.7 +/- 1.5, and 18.3 +/- 2.7 min/l, respectively, in the Ent1(+/+) mice and 18.9 +/- 2.8, 13.0 +/- 0.5, and 12.2 +/- 1.0 min/l, respectively, in the Ent1(-/-) mice.",The role of nucleoside transporters in the erythrocyte disposition and oral absorption of ribavirin in the wild-type and equilibrative nucleoside transporter 1-/- mice. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19602549/),[min] / [l],18.9,179537,DB00811,Ribavirin
,19602549,dose-normalized plasma AUC(0-12 h),"After oral administration of three different doses, 0.024, 0.24, and 6.1 mg/kg, we found that the dose-normalized plasma AUC(0-12 h) of ribavirin was 69.7 +/- 12.0, 20.7 +/- 1.5, and 18.3 +/- 2.7 min/l, respectively, in the Ent1(+/+) mice and 18.9 +/- 2.8, 13.0 +/- 0.5, and 12.2 +/- 1.0 min/l, respectively, in the Ent1(-/-) mice.",The role of nucleoside transporters in the erythrocyte disposition and oral absorption of ribavirin in the wild-type and equilibrative nucleoside transporter 1-/- mice. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19602549/),[min] / [l],13.0,179538,DB00811,Ribavirin
,19602549,dose-normalized plasma AUC(0-12 h),"After oral administration of three different doses, 0.024, 0.24, and 6.1 mg/kg, we found that the dose-normalized plasma AUC(0-12 h) of ribavirin was 69.7 +/- 12.0, 20.7 +/- 1.5, and 18.3 +/- 2.7 min/l, respectively, in the Ent1(+/+) mice and 18.9 +/- 2.8, 13.0 +/- 0.5, and 12.2 +/- 1.0 min/l, respectively, in the Ent1(-/-) mice.",The role of nucleoside transporters in the erythrocyte disposition and oral absorption of ribavirin in the wild-type and equilibrative nucleoside transporter 1-/- mice. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19602549/),[min] / [l],12.2,179539,DB00811,Ribavirin
,25801562,Cmin,"The median ribavirin Cmin for triple therapy (4.08 μg/ml; range, 2.14 to 5.56 μg/ml) was higher than that observed after telaprevir withdrawal (1.96 μg/ml; range, 0.41 to 3.45 μg/ml) (P < 0.001) and that observed for 125 HCV-1/HIV-coinfected patients treated only with pegIFN-α plus ribavirin (1.65 μg/ml; range, 0.41 to 5.56 μg/ml) (P < 0.001).",Telaprevir and ribavirin interaction: higher ribavirin levels are not only due to renal dysfunction during triple therapy. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25801562/),[μg] / [ml],4.08,183612,DB00811,Ribavirin
,25801562,Cmin,"The median ribavirin Cmin for triple therapy (4.08 μg/ml; range, 2.14 to 5.56 μg/ml) was higher than that observed after telaprevir withdrawal (1.96 μg/ml; range, 0.41 to 3.45 μg/ml) (P < 0.001) and that observed for 125 HCV-1/HIV-coinfected patients treated only with pegIFN-α plus ribavirin (1.65 μg/ml; range, 0.41 to 5.56 μg/ml) (P < 0.001).",Telaprevir and ribavirin interaction: higher ribavirin levels are not only due to renal dysfunction during triple therapy. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25801562/),[μg] / [ml],1.96,183613,DB00811,Ribavirin
,25801562,Cmin,"The median ribavirin Cmin for triple therapy (4.08 μg/ml; range, 2.14 to 5.56 μg/ml) was higher than that observed after telaprevir withdrawal (1.96 μg/ml; range, 0.41 to 3.45 μg/ml) (P < 0.001) and that observed for 125 HCV-1/HIV-coinfected patients treated only with pegIFN-α plus ribavirin (1.65 μg/ml; range, 0.41 to 5.56 μg/ml) (P < 0.001).",Telaprevir and ribavirin interaction: higher ribavirin levels are not only due to renal dysfunction during triple therapy. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25801562/),[μg] / [ml],1.65,183614,DB00811,Ribavirin
,33492492,binding energy,"4-O-(6-galloylglucoside) gave binding energy values of - 8.4, - 6.8, - 8.9, - 9.1, and - 7.5 kcal/mol against Mpro, nsp3, nsp12, nsp13, and nsp15 respectively.",Molecular docking studies of some selected gallic acid derivatives against five non-structural proteins of novel coronavirus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33492492/),[kcal] / [mol],-,185697,DB00811,Ribavirin
,33492492,binding energy,"4-O-(6-galloylglucoside) gave binding energy values of - 8.4, - 6.8, - 8.9, - 9.1, and - 7.5 kcal/mol against Mpro, nsp3, nsp12, nsp13, and nsp15 respectively.",Molecular docking studies of some selected gallic acid derivatives against five non-structural proteins of novel coronavirus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33492492/),[kcal] / [mol],8.4,185698,DB00811,Ribavirin
,33492492,binding energy,"4-O-(6-galloylglucoside) gave binding energy values of - 8.4, - 6.8, - 8.9, - 9.1, and - 7.5 kcal/mol against Mpro, nsp3, nsp12, nsp13, and nsp15 respectively.",Molecular docking studies of some selected gallic acid derivatives against five non-structural proteins of novel coronavirus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33492492/),[kcal] / [mol],6.8,185699,DB00811,Ribavirin
,33492492,binding energy,"4-O-(6-galloylglucoside) gave binding energy values of - 8.4, - 6.8, - 8.9, - 9.1, and - 7.5 kcal/mol against Mpro, nsp3, nsp12, nsp13, and nsp15 respectively.",Molecular docking studies of some selected gallic acid derivatives against five non-structural proteins of novel coronavirus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33492492/),[kcal] / [mol],8.9,185700,DB00811,Ribavirin
,33492492,binding energy,"4-O-(6-galloylglucoside) gave binding energy values of - 8.4, - 6.8, - 8.9, - 9.1, and - 7.5 kcal/mol against Mpro, nsp3, nsp12, nsp13, and nsp15 respectively.",Molecular docking studies of some selected gallic acid derivatives against five non-structural proteins of novel coronavirus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33492492/),[kcal] / [mol],9.1,185701,DB00811,Ribavirin
,33492492,binding energy,"4-O-(6-galloylglucoside) gave binding energy values of - 8.4, - 6.8, - 8.9, - 9.1, and - 7.5 kcal/mol against Mpro, nsp3, nsp12, nsp13, and nsp15 respectively.",Molecular docking studies of some selected gallic acid derivatives against five non-structural proteins of novel coronavirus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33492492/),[kcal] / [mol],7.5,185702,DB00811,Ribavirin
,12654676,oral absorption,"The oral absorption and bioavailability were 83 and 59%, respectively, in rats and 87 and 55%, respectively, in monkeys.",Pharmacokinetics and metabolism of [(14)C]ribavirin in rats and cynomolgus monkeys. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12654676/),%,83,186339,DB00811,Ribavirin
,12654676,oral absorption,"The oral absorption and bioavailability were 83 and 59%, respectively, in rats and 87 and 55%, respectively, in monkeys.",Pharmacokinetics and metabolism of [(14)C]ribavirin in rats and cynomolgus monkeys. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12654676/),%,87,186340,DB00811,Ribavirin
,12654676,bioavailability,"The oral absorption and bioavailability were 83 and 59%, respectively, in rats and 87 and 55%, respectively, in monkeys.",Pharmacokinetics and metabolism of [(14)C]ribavirin in rats and cynomolgus monkeys. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12654676/),%,59,186341,DB00811,Ribavirin
,12654676,bioavailability,"The oral absorption and bioavailability were 83 and 59%, respectively, in rats and 87 and 55%, respectively, in monkeys.",Pharmacokinetics and metabolism of [(14)C]ribavirin in rats and cynomolgus monkeys. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12654676/),%,87,186342,DB00811,Ribavirin
,12654676,bioavailability,"The oral absorption and bioavailability were 83 and 59%, respectively, in rats and 87 and 55%, respectively, in monkeys.",Pharmacokinetics and metabolism of [(14)C]ribavirin in rats and cynomolgus monkeys. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12654676/),%,55,186343,DB00811,Ribavirin
,12654676,elimination half-life (t([1/2])),"After i.v. administration, the elimination half-life (t([1/2])) was 9.9 h in rats and 130 h in monkeys and the total body clearance was 2,600 ml/h/kg in rats and 224 ml/h/kg in monkeys.",Pharmacokinetics and metabolism of [(14)C]ribavirin in rats and cynomolgus monkeys. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12654676/),h,9.9,186344,DB00811,Ribavirin
,12654676,elimination half-life (t([1/2])),"After i.v. administration, the elimination half-life (t([1/2])) was 9.9 h in rats and 130 h in monkeys and the total body clearance was 2,600 ml/h/kg in rats and 224 ml/h/kg in monkeys.",Pharmacokinetics and metabolism of [(14)C]ribavirin in rats and cynomolgus monkeys. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12654676/),h,130,186345,DB00811,Ribavirin
,12654676,total body clearance,"After i.v. administration, the elimination half-life (t([1/2])) was 9.9 h in rats and 130 h in monkeys and the total body clearance was 2,600 ml/h/kg in rats and 224 ml/h/kg in monkeys.",Pharmacokinetics and metabolism of [(14)C]ribavirin in rats and cynomolgus monkeys. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12654676/),[ml] / [h·kg],"2,600",186346,DB00811,Ribavirin
,12654676,total body clearance,"After i.v. administration, the elimination half-life (t([1/2])) was 9.9 h in rats and 130 h in monkeys and the total body clearance was 2,600 ml/h/kg in rats and 224 ml/h/kg in monkeys.",Pharmacokinetics and metabolism of [(14)C]ribavirin in rats and cynomolgus monkeys. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12654676/),[ml] / [h·kg],224,186347,DB00811,Ribavirin
,12654676,apparent volume of distribution,The apparent volume of distribution was 11.4 liter/kg in rats and 29.4 liter/kg in monkeys.,Pharmacokinetics and metabolism of [(14)C]ribavirin in rats and cynomolgus monkeys. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12654676/),[l] / [kg],11.4,186348,DB00811,Ribavirin
,12654676,apparent volume of distribution,The apparent volume of distribution was 11.4 liter/kg in rats and 29.4 liter/kg in monkeys.,Pharmacokinetics and metabolism of [(14)C]ribavirin in rats and cynomolgus monkeys. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12654676/),[l] / [kg],29.4,186349,DB00811,Ribavirin
,23896477,tmax (time to maximum concentration of drug in serum),"Administration of GSK2336805 with food had no effect on plasma GSK2336805 exposure; however, absorption was delayed, with a median tmax (time to maximum concentration of drug in serum) of 4.5 versus 2.0 h.","Safety, tolerability, pharmacokinetics, and antiviral activity of GSK2336805, an inhibitor of hepatitis C virus (HCV) NS5A, in healthy subjects and subjects chronically infected with HCV genotype 1. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23896477/),h,4.5,191365,DB00811,Ribavirin
,23896477,tmax (time to maximum concentration of drug in serum),"Administration of GSK2336805 with food had no effect on plasma GSK2336805 exposure; however, absorption was delayed, with a median tmax (time to maximum concentration of drug in serum) of 4.5 versus 2.0 h.","Safety, tolerability, pharmacokinetics, and antiviral activity of GSK2336805, an inhibitor of hepatitis C virus (HCV) NS5A, in healthy subjects and subjects chronically infected with HCV genotype 1. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23896477/),h,2.0,191366,DB00811,Ribavirin
,26158282,Ctrough plasma concentrations,"Median telaprevir Ctrough plasma concentrations were 2579 ng/mL and 2233 ng/mL for the pharmacologically more active S, and R, enantiomers, respectively, with median S/R plasma ratio of 1.11.",Intracellular and Plasma Trough Concentration and Pharmacogenetics of Telaprevir. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26158282/),[ng] / [ml],2579,193087,DB00811,Ribavirin
,26158282,Ctrough plasma concentrations,"Median telaprevir Ctrough plasma concentrations were 2579 ng/mL and 2233 ng/mL for the pharmacologically more active S, and R, enantiomers, respectively, with median S/R plasma ratio of 1.11.",Intracellular and Plasma Trough Concentration and Pharmacogenetics of Telaprevir. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26158282/),[ng] / [ml],2233,193088,DB00811,Ribavirin
,26158282,S/R,"Median telaprevir Ctrough plasma concentrations were 2579 ng/mL and 2233 ng/mL for the pharmacologically more active S, and R, enantiomers, respectively, with median S/R plasma ratio of 1.11.",Intracellular and Plasma Trough Concentration and Pharmacogenetics of Telaprevir. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26158282/),,1.11,193089,DB00811,Ribavirin
,26158282,plasma ratio,"Median telaprevir Ctrough plasma concentrations were 2579 ng/mL and 2233 ng/mL for the pharmacologically more active S, and R, enantiomers, respectively, with median S/R plasma ratio of 1.11.",Intracellular and Plasma Trough Concentration and Pharmacogenetics of Telaprevir. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26158282/),,1.11,193090,DB00811,Ribavirin
,26158282,S/R,"In PBMC, the medians were 6863 ng/mL and 1096 ng/mL for S and R, respectively, with median S/R being 5.73.",Intracellular and Plasma Trough Concentration and Pharmacogenetics of Telaprevir. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26158282/),,5.73,193091,DB00811,Ribavirin
,26158282,P,The PBMC:plasma ratio for S was 2.59 for R. Plasma ribavirin concentrations were directly correlated with plasma S-telaprevir concentrations.,Intracellular and Plasma Trough Concentration and Pharmacogenetics of Telaprevir. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26158282/),,2.59,193092,DB00811,Ribavirin
,3986812,Terminal,Terminal-phase mean harmonic half-life was 8.0 h.,Phase I clinical study with pharmacokinetic analysis of 2-beta-D-ribofuranosylthiazole-4-carboxamide (NSC 286193) administered as a five-day infusion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3986812/),h,8.0,196495,DB00811,Ribavirin
,3593893,percentage,The percentage of tiazofurin bound to plasma proteins remained constant at approximately 15 per cent following administration to healthy mongrel dogs.,Pharmacokinetics of tiazofurin in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3593893/),%,15,197046,DB00811,Ribavirin
,3593893,elimination rate constant (K),"The mean pharmacokinetic parameters of elimination rate constant (K), effective half-life (t 1/2), mean residence time (MRT) and the time to reach peak plasma level (tmax--after oral administration) were 0.32 +/- 0.04 h-1, 2.24 +/- 0.25 h, 3.23 +/- 0.36 h, and 1.78 +/- 0.50 h, respectively.",Pharmacokinetics of tiazofurin in dogs. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3593893/),1/[h],0.32,197047,DB00811,Ribavirin
,3593893,effective half-life (t 1/2),"The mean pharmacokinetic parameters of elimination rate constant (K), effective half-life (t 1/2), mean residence time (MRT) and the time to reach peak plasma level (tmax--after oral administration) were 0.32 +/- 0.04 h-1, 2.24 +/- 0.25 h, 3.23 +/- 0.36 h, and 1.78 +/- 0.50 h, respectively.",Pharmacokinetics of tiazofurin in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3593893/),h,2.24,197048,DB00811,Ribavirin
,3593893,effective half-life (t 1/2),"The mean pharmacokinetic parameters of elimination rate constant (K), effective half-life (t 1/2), mean residence time (MRT) and the time to reach peak plasma level (tmax--after oral administration) were 0.32 +/- 0.04 h-1, 2.24 +/- 0.25 h, 3.23 +/- 0.36 h, and 1.78 +/- 0.50 h, respectively.",Pharmacokinetics of tiazofurin in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3593893/),h,3.23,197049,DB00811,Ribavirin
,3593893,mean residence time (MRT),"The mean pharmacokinetic parameters of elimination rate constant (K), effective half-life (t 1/2), mean residence time (MRT) and the time to reach peak plasma level (tmax--after oral administration) were 0.32 +/- 0.04 h-1, 2.24 +/- 0.25 h, 3.23 +/- 0.36 h, and 1.78 +/- 0.50 h, respectively.",Pharmacokinetics of tiazofurin in dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3593893/),h,3.23,197050,DB00811,Ribavirin
,3593893,time to reach peak plasma level (tmax--,"The mean pharmacokinetic parameters of elimination rate constant (K), effective half-life (t 1/2), mean residence time (MRT) and the time to reach peak plasma level (tmax--after oral administration) were 0.32 +/- 0.04 h-1, 2.24 +/- 0.25 h, 3.23 +/- 0.36 h, and 1.78 +/- 0.50 h, respectively.",Pharmacokinetics of tiazofurin in dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3593893/),h,1.78,197051,DB00811,Ribavirin
,3593893,apparent volume of distribution at steady state,The apparent volume of distribution at steady state was 0.98 +/- 0.30 1 kg-1 and the plasma clearance was 5.24 +/- 2.39 ml min-1 kg-1.,Pharmacokinetics of tiazofurin in dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3593893/),[1] / [kg],0.98,197052,DB00811,Ribavirin
,3593893,plasma clearance,The apparent volume of distribution at steady state was 0.98 +/- 0.30 1 kg-1 and the plasma clearance was 5.24 +/- 2.39 ml min-1 kg-1.,Pharmacokinetics of tiazofurin in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3593893/),[ml] / [kg·min],5.24,197053,DB00811,Ribavirin
,16761329,EC50,"Although PEG-IFN concentrations and pharmacokinetic parameters were similar in sustained virological responders (SVRs) and nonresponders (NRs), the PEG-IFN alpha-2b concentration that decreases HCV production by 50% (EC50) was lower in SVRs compared with NRs (0.04 vs. 0.45 microg/L [P = .014]).",Pharmacodynamics of PEG-IFN alpha differentiate HIV/HCV coinfected sustained virological responders from nonresponders. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16761329/),[μg] / [l],0.04,197816,DB00811,Ribavirin
,16761329,EC50,"Although PEG-IFN concentrations and pharmacokinetic parameters were similar in sustained virological responders (SVRs) and nonresponders (NRs), the PEG-IFN alpha-2b concentration that decreases HCV production by 50% (EC50) was lower in SVRs compared with NRs (0.04 vs. 0.45 microg/L [P = .014]).",Pharmacodynamics of PEG-IFN alpha differentiate HIV/HCV coinfected sustained virological responders from nonresponders. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16761329/),[μg] / [l],0.45,197817,DB00811,Ribavirin
,1568787,peak plasma concentrations,"In leukemic patients during and after infusion at doses of 1,100, 2,200 and 3,300 mg/m2 tiazofurin peak plasma concentrations were 245, 441 and 736 microM, respectively, values one-half of those calculated from other reports with a 10-min bolus administration.",Clinical pharmacokinetic study of tiazofurin administered as a 1-hour infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1568787/),μM,245,197840,DB00811,Ribavirin
,1568787,peak plasma concentrations,"In leukemic patients during and after infusion at doses of 1,100, 2,200 and 3,300 mg/m2 tiazofurin peak plasma concentrations were 245, 441 and 736 microM, respectively, values one-half of those calculated from other reports with a 10-min bolus administration.",Clinical pharmacokinetic study of tiazofurin administered as a 1-hour infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1568787/),μM,441,197841,DB00811,Ribavirin
,1568787,peak plasma concentrations,"In leukemic patients during and after infusion at doses of 1,100, 2,200 and 3,300 mg/m2 tiazofurin peak plasma concentrations were 245, 441 and 736 microM, respectively, values one-half of those calculated from other reports with a 10-min bolus administration.",Clinical pharmacokinetic study of tiazofurin administered as a 1-hour infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1568787/),μM,736,197842,DB00811,Ribavirin
,1568787,alpha t1/2,"In our 1-hr infusion method, biphasic pharmacokinetics were noted with alpha t1/2 and beta t1/2 of 0.5 and 6.2 hr, and tiazofurin was eliminated at a faster rate than in previous trials with continuous infusion.",Clinical pharmacokinetic study of tiazofurin administered as a 1-hour infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1568787/),h,0.5,197843,DB00811,Ribavirin
,1568787,beta t1/2,"In our 1-hr infusion method, biphasic pharmacokinetics were noted with alpha t1/2 and beta t1/2 of 0.5 and 6.2 hr, and tiazofurin was eliminated at a faster rate than in previous trials with continuous infusion.",Clinical pharmacokinetic study of tiazofurin administered as a 1-hour infusion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1568787/),h,6.2,197844,DB00811,Ribavirin
,22163158,maximum plasma concentration,"In trial 1, following a single dose of peginterferon alfa-2a, the maximum plasma concentration was 16.1 ± 5.3 ng/mL (mean ± standard deviation), and area under the concentration time curve (0-168 hours) was 1996 ± 613 ng · hour/mL, similar to that reported using a vial/syringe or prefilled syringe.","Evaluation of pharmacokinetics, user handling, and tolerability of peginterferon alfa-2a (40 kDa) delivered via a disposable autoinjector device. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22163158/),[ng] / [ml],16.1,198531,DB00811,Ribavirin
,22163158,area under the concentration time curve (0-168 hours),"In trial 1, following a single dose of peginterferon alfa-2a, the maximum plasma concentration was 16.1 ± 5.3 ng/mL (mean ± standard deviation), and area under the concentration time curve (0-168 hours) was 1996 ± 613 ng · hour/mL, similar to that reported using a vial/syringe or prefilled syringe.","Evaluation of pharmacokinetics, user handling, and tolerability of peginterferon alfa-2a (40 kDa) delivered via a disposable autoinjector device. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22163158/),[h·ng] / [ml],1996,198532,DB00811,Ribavirin
,16801414,time to maximum concentration,"Viramidine was rapidly absorbed, with a time to maximum concentration of the drug in plasma of 1.5 h.","Absorption, metabolism, and excretion of [14C]viramidine in humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16801414/),h,1.5,198598,DB00811,Ribavirin
,21145839,maximal viral load (VL),"In treatment-naïve patients, median maximal viral load (VL) reductions during 14-day monotherapy were -3.0, -3.6, -3.7, and -4.2 log(10) for the 20, 48, 120, and 240 mg groups.","Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21145839/),log(10),3.0,204539,DB00811,Ribavirin
,21145839,maximal viral load (VL),"In treatment-naïve patients, median maximal viral load (VL) reductions during 14-day monotherapy were -3.0, -3.6, -3.7, and -4.2 log(10) for the 20, 48, 120, and 240 mg groups.","Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21145839/),log(10),3.6,204540,DB00811,Ribavirin
,21145839,maximal viral load (VL),"In treatment-naïve patients, median maximal viral load (VL) reductions during 14-day monotherapy were -3.0, -3.6, -3.7, and -4.2 log(10) for the 20, 48, 120, and 240 mg groups.","Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21145839/),log(10),3.7,204541,DB00811,Ribavirin
<,21145839,VL,"In treatment-experienced patients, treatment with BI201335 and PegIFN/RBV achieved VL<25 IU/ml at Day 28 in 3/6, 4/7, and 5/6 patients in the 48, 120, and 240 mg dose groups.","Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21145839/),[iu] / [ml],25,204542,DB00811,Ribavirin
,18651600,constant flow rate,"The chromatographic separation was achieved within 4.5 min using a SinoChrom ODS-BP column (4.6 x 150 mm, 5 microm) with acetonitrile-water (1 mmol/L ammonium acetate buffer, 0.1% formic acid; 15:85, v/v) at a constant flow rate of 0.8 mL/min.",Rapid and sensitive HPLC-MS/MS method for pharmacokinetic assessment of ribavirin in healthy Chinese. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18651600/),[ml] / [min],0.8,204891,DB00811,Ribavirin
,18651600,m/,"The MRM pairs were m/z 245.2 --> m/z 113.1 for ribavirin and m/z 226.1 --> m/z 152.1 for acyclovir (internal standard), respectively, with dwell times of 200 ms for each transition.",Rapid and sensitive HPLC-MS/MS method for pharmacokinetic assessment of ribavirin in healthy Chinese. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18651600/),,245.2,204892,DB00811,Ribavirin
,18651600,m/z,"The MRM pairs were m/z 245.2 --> m/z 113.1 for ribavirin and m/z 226.1 --> m/z 152.1 for acyclovir (internal standard), respectively, with dwell times of 200 ms for each transition.",Rapid and sensitive HPLC-MS/MS method for pharmacokinetic assessment of ribavirin in healthy Chinese. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18651600/),,226.1,204893,DB00811,Ribavirin
,18651600,m/z,"The MRM pairs were m/z 245.2 --> m/z 113.1 for ribavirin and m/z 226.1 --> m/z 152.1 for acyclovir (internal standard), respectively, with dwell times of 200 ms for each transition.",Rapid and sensitive HPLC-MS/MS method for pharmacokinetic assessment of ribavirin in healthy Chinese. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18651600/),,152.1,204894,DB00811,Ribavirin
,18651600,dwell times,"The MRM pairs were m/z 245.2 --> m/z 113.1 for ribavirin and m/z 226.1 --> m/z 152.1 for acyclovir (internal standard), respectively, with dwell times of 200 ms for each transition.",Rapid and sensitive HPLC-MS/MS method for pharmacokinetic assessment of ribavirin in healthy Chinese. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18651600/),ms,200,204895,DB00811,Ribavirin
,18651600,time to maximum concentration,The mean time to maximum concentration was about 1.25 h.,Rapid and sensitive HPLC-MS/MS method for pharmacokinetic assessment of ribavirin in healthy Chinese. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18651600/),h,1.25,204896,DB00811,Ribavirin
,18651600,maximum concentration of drug,The mean maximum concentration of drug in plasma for oral ribavirin was 250 ng/mL.,Rapid and sensitive HPLC-MS/MS method for pharmacokinetic assessment of ribavirin in healthy Chinese. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18651600/),[ng] / [ml],250,204897,DB00811,Ribavirin
,18651600,elimination half-life,The mean elimination half-life was 43.6 h.,Rapid and sensitive HPLC-MS/MS method for pharmacokinetic assessment of ribavirin in healthy Chinese. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18651600/),h,43.6,204898,DB00811,Ribavirin
,24145880,terminal half-life,"The ATV AUC(0-12), C(max), and C(min) values were 39% (13%-66%), 19% (8%-59%), and 48% (1%-96%) higher, respectively, with a significantly shorter terminal half-life (22.6 hours vs 10.4 hours).",Role of ritonavir in the drug interactions between telaprevir and ritonavir-boosted atazanavir. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24145880/),h,22.6,206718,DB00811,Ribavirin
,24145880,terminal half-life,"The ATV AUC(0-12), C(max), and C(min) values were 39% (13%-66%), 19% (8%-59%), and 48% (1%-96%) higher, respectively, with a significantly shorter terminal half-life (22.6 hours vs 10.4 hours).",Role of ritonavir in the drug interactions between telaprevir and ritonavir-boosted atazanavir. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24145880/),h,10.4,206719,DB00811,Ribavirin
,22639111,CL/F,"The typical population parameters were CL/F (19.0 L/h), Vc/F (1,130 L), Vp/F (4,020 L), and Q/F (38.6).",Population pharmacokinetics and pharmacodynamics of ribavirin in patients with chronic hepatitis C genotype 1 infection. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22639111/),[l] / [h],19.0,207138,DB00811,Ribavirin
,22639111,Vc/F,"The typical population parameters were CL/F (19.0 L/h), Vc/F (1,130 L), Vp/F (4,020 L), and Q/F (38.6).",Population pharmacokinetics and pharmacodynamics of ribavirin in patients with chronic hepatitis C genotype 1 infection. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22639111/),l,"1,130",207139,DB00811,Ribavirin
,22639111,Vp/F,"The typical population parameters were CL/F (19.0 L/h), Vc/F (1,130 L), Vp/F (4,020 L), and Q/F (38.6).",Population pharmacokinetics and pharmacodynamics of ribavirin in patients with chronic hepatitis C genotype 1 infection. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22639111/),l,"4,020",207140,DB00811,Ribavirin
,22639111,Q/F,"The typical population parameters were CL/F (19.0 L/h), Vc/F (1,130 L), Vp/F (4,020 L), and Q/F (38.6).",Population pharmacokinetics and pharmacodynamics of ribavirin in patients with chronic hepatitis C genotype 1 infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22639111/),,38.6,207141,DB00811,Ribavirin
,24602156,RVR,"Among non-CC genotype patients, RVR rates were 26.5% (14.6-43.1%), 52.3% (43.0-61.3%) and 5.7% (2.2-13.8%), and cEVR rates were 76.5% (60.0-87.6%), 84.6% (76.6-90.1%) and 28.6% (19.3-40.1%), respectively.",Understanding the effect of the HCV polymerase inhibitor mericitabine on early viral kinetics in the phase 2 JUMP-C and PROPEL studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24602156/),%,26,214067,DB00811,Ribavirin
,24602156,RVR,"Among non-CC genotype patients, RVR rates were 26.5% (14.6-43.1%), 52.3% (43.0-61.3%) and 5.7% (2.2-13.8%), and cEVR rates were 76.5% (60.0-87.6%), 84.6% (76.6-90.1%) and 28.6% (19.3-40.1%), respectively.",Understanding the effect of the HCV polymerase inhibitor mericitabine on early viral kinetics in the phase 2 JUMP-C and PROPEL studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24602156/),%,52,214068,DB00811,Ribavirin
,24602156,cEVR,"Among non-CC genotype patients, RVR rates were 26.5% (14.6-43.1%), 52.3% (43.0-61.3%) and 5.7% (2.2-13.8%), and cEVR rates were 76.5% (60.0-87.6%), 84.6% (76.6-90.1%) and 28.6% (19.3-40.1%), respectively.",Understanding the effect of the HCV polymerase inhibitor mericitabine on early viral kinetics in the phase 2 JUMP-C and PROPEL studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24602156/),%,76.,214069,DB00811,Ribavirin
,24602156,cEVR,"Among non-CC genotype patients, RVR rates were 26.5% (14.6-43.1%), 52.3% (43.0-61.3%) and 5.7% (2.2-13.8%), and cEVR rates were 76.5% (60.0-87.6%), 84.6% (76.6-90.1%) and 28.6% (19.3-40.1%), respectively.",Understanding the effect of the HCV polymerase inhibitor mericitabine on early viral kinetics in the phase 2 JUMP-C and PROPEL studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24602156/),%,84.6,214070,DB00811,Ribavirin
,24602156,cEVR,"Among non-CC genotype patients, RVR rates were 26.5% (14.6-43.1%), 52.3% (43.0-61.3%) and 5.7% (2.2-13.8%), and cEVR rates were 76.5% (60.0-87.6%), 84.6% (76.6-90.1%) and 28.6% (19.3-40.1%), respectively.",Understanding the effect of the HCV polymerase inhibitor mericitabine on early viral kinetics in the phase 2 JUMP-C and PROPEL studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24602156/),%,28.6,214071,DB00811,Ribavirin
,3802111,beta-half-time,"Pharmacokinetic analysis revealed tiazofurin plasma elimination to be at least biphasic, with a beta-half-time of 4.2 hours; most of an injected dose could be recovered from the urine as unaltered compound within 24 hours.","Phase I trial of tiazofurin administered by i.v. bolus daily for 5 days, with pharmacokinetic evaluation. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3802111/),h,4.2,215224,DB00811,Ribavirin
,25667954,EC50,Among tested compounds 4'-chloromethyl-2'-deoxy-2'-fluorocytidine (2c) exhibited the most promising activity in the RSV replicon assay with an EC50 of 0.15 μM.,"Discovery of 4'-chloromethyl-2'-deoxy-3',5'-di-O-isobutyryl-2'-fluorocytidine (ALS-8176), a first-in-class RSV polymerase inhibitor for treatment of human respiratory syncytial virus infection. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25667954/),μM,0.15,215812,DB00811,Ribavirin
,25667954,IC50,The 5'-triphosphate of 2c (2c-TP) inhibited RSV polymerase with an IC50 of 0.02 μM without appreciable inhibition of human DNA and RNA polymerases at 100 μM.,"Discovery of 4'-chloromethyl-2'-deoxy-3',5'-di-O-isobutyryl-2'-fluorocytidine (ALS-8176), a first-in-class RSV polymerase inhibitor for treatment of human respiratory syncytial virus infection. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25667954/),μM,0.02,215813,DB00811,Ribavirin
exceeding,34197863,selectivity indices,"In Tacaribe virus (TCRV) pseudotyped and native virus assays, the ARN compounds were active in the low to sub-nanomolar range with selectivity indices exceeding 1000.",Potent inhibition of arenavirus infection by a novel fusion inhibitor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34197863/),,1000,216054,DB00811,Ribavirin
,29589331,clearance (CL/F),"A typical value for ASV clearance (CL/F) was 50.8 L/h, increasing by 43% after 2 days to a CL/F of 72.5 L/h at steady-state, likely due to auto-induction of cytochrome P450 3A4 (CYP3A4).",Population Pharmacokinetic Analysis of Asunaprevir in Subjects with Hepatitis C Virus Infection. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29589331/),[l] / [h],50.8,221961,DB00811,Ribavirin
,29589331,CL/F,"A typical value for ASV clearance (CL/F) was 50.8 L/h, increasing by 43% after 2 days to a CL/F of 72.5 L/h at steady-state, likely due to auto-induction of cytochrome P450 3A4 (CYP3A4).",Population Pharmacokinetic Analysis of Asunaprevir in Subjects with Hepatitis C Virus Infection. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29589331/),[l] / [h],72.5,221962,DB00811,Ribavirin
,21551316,First-order absorption rate constant,"First-order absorption rate constant (0.0148 h(-1)), apparent clearance (38.9 mL/h), and apparent volume of distribution (11.6 L) had interindividual variances (coefficient of variation) of 21%, 34%, and 24%, respectively.",Population pharmacokinetics and exposure-response of albinterferon alfa-2b. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21551316/),1/[h],0.0148,222668,DB00811,Ribavirin
,21551316,apparent clearance,"First-order absorption rate constant (0.0148 h(-1)), apparent clearance (38.9 mL/h), and apparent volume of distribution (11.6 L) had interindividual variances (coefficient of variation) of 21%, 34%, and 24%, respectively.",Population pharmacokinetics and exposure-response of albinterferon alfa-2b. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21551316/),[ml] / [h],38.9,222669,DB00811,Ribavirin
,21551316,apparent volume of distribution,"First-order absorption rate constant (0.0148 h(-1)), apparent clearance (38.9 mL/h), and apparent volume of distribution (11.6 L) had interindividual variances (coefficient of variation) of 21%, 34%, and 24%, respectively.",Population pharmacokinetics and exposure-response of albinterferon alfa-2b. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21551316/),l,11.6,222670,DB00811,Ribavirin
,30181726,Cmax,"Pharmacokinetics for collection period 1 demonstrated a calculated Cmax of 11.99 mg/L, an AUC0-24 of 43.32 mg·hr/L, ke 0.26 hr-1, t½ 2.69 hr, Vd 10.04 L (2.92 L/kg, using patient's dosing weight 3.43 kg), CLT 43.47 mL/min, and CLCVVH 6.75 mL/min.",Intravenous Ribavirin for Parainfluenza and Respiratory Syncytial Virus in an Infant Receiving Extracorporeal Membrane Oxygenation and Continuous Renal Replacement Therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30181726/),[mg] / [l],11.99,223878,DB00811,Ribavirin
,30181726,AUC0-24,"Pharmacokinetics for collection period 1 demonstrated a calculated Cmax of 11.99 mg/L, an AUC0-24 of 43.32 mg·hr/L, ke 0.26 hr-1, t½ 2.69 hr, Vd 10.04 L (2.92 L/kg, using patient's dosing weight 3.43 kg), CLT 43.47 mL/min, and CLCVVH 6.75 mL/min.",Intravenous Ribavirin for Parainfluenza and Respiratory Syncytial Virus in an Infant Receiving Extracorporeal Membrane Oxygenation and Continuous Renal Replacement Therapy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30181726/),[h·mg] / [l],43.32,223879,DB00811,Ribavirin
,30181726,ke,"Pharmacokinetics for collection period 1 demonstrated a calculated Cmax of 11.99 mg/L, an AUC0-24 of 43.32 mg·hr/L, ke 0.26 hr-1, t½ 2.69 hr, Vd 10.04 L (2.92 L/kg, using patient's dosing weight 3.43 kg), CLT 43.47 mL/min, and CLCVVH 6.75 mL/min.",Intravenous Ribavirin for Parainfluenza and Respiratory Syncytial Virus in an Infant Receiving Extracorporeal Membrane Oxygenation and Continuous Renal Replacement Therapy. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30181726/),1/[h],0.26,223880,DB00811,Ribavirin
,30181726,t½,"Pharmacokinetics for collection period 1 demonstrated a calculated Cmax of 11.99 mg/L, an AUC0-24 of 43.32 mg·hr/L, ke 0.26 hr-1, t½ 2.69 hr, Vd 10.04 L (2.92 L/kg, using patient's dosing weight 3.43 kg), CLT 43.47 mL/min, and CLCVVH 6.75 mL/min.",Intravenous Ribavirin for Parainfluenza and Respiratory Syncytial Virus in an Infant Receiving Extracorporeal Membrane Oxygenation and Continuous Renal Replacement Therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30181726/),h,2.69,223881,DB00811,Ribavirin
,30181726,Vd,"Pharmacokinetics for collection period 1 demonstrated a calculated Cmax of 11.99 mg/L, an AUC0-24 of 43.32 mg·hr/L, ke 0.26 hr-1, t½ 2.69 hr, Vd 10.04 L (2.92 L/kg, using patient's dosing weight 3.43 kg), CLT 43.47 mL/min, and CLCVVH 6.75 mL/min.",Intravenous Ribavirin for Parainfluenza and Respiratory Syncytial Virus in an Infant Receiving Extracorporeal Membrane Oxygenation and Continuous Renal Replacement Therapy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30181726/),l,10.04,223882,DB00811,Ribavirin
,30181726,CLT,"Pharmacokinetics for collection period 1 demonstrated a calculated Cmax of 11.99 mg/L, an AUC0-24 of 43.32 mg·hr/L, ke 0.26 hr-1, t½ 2.69 hr, Vd 10.04 L (2.92 L/kg, using patient's dosing weight 3.43 kg), CLT 43.47 mL/min, and CLCVVH 6.75 mL/min.",Intravenous Ribavirin for Parainfluenza and Respiratory Syncytial Virus in an Infant Receiving Extracorporeal Membrane Oxygenation and Continuous Renal Replacement Therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30181726/),[ml] / [min],43.47,223883,DB00811,Ribavirin
,30181726,CLCVVH,"Pharmacokinetics for collection period 1 demonstrated a calculated Cmax of 11.99 mg/L, an AUC0-24 of 43.32 mg·hr/L, ke 0.26 hr-1, t½ 2.69 hr, Vd 10.04 L (2.92 L/kg, using patient's dosing weight 3.43 kg), CLT 43.47 mL/min, and CLCVVH 6.75 mL/min.",Intravenous Ribavirin for Parainfluenza and Respiratory Syncytial Virus in an Infant Receiving Extracorporeal Membrane Oxygenation and Continuous Renal Replacement Therapy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30181726/),[ml] / [min],6.75,223884,DB00811,Ribavirin
,30181726,Cmax,"Pharmacokinetics for collection period 2 demonstrated a calculated Cmax of 10.31 mg/L, AUC0-6 of 52.55 mg· hr/L, ke 0.06 hr-1, t½ 10.69 hr, Vd 17.5 L (5.1 L/kg), and CLT 17.44 mL/min.",Intravenous Ribavirin for Parainfluenza and Respiratory Syncytial Virus in an Infant Receiving Extracorporeal Membrane Oxygenation and Continuous Renal Replacement Therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30181726/),[mg] / [l],10.31,223885,DB00811,Ribavirin
,30181726,AUC0-6,"Pharmacokinetics for collection period 2 demonstrated a calculated Cmax of 10.31 mg/L, AUC0-6 of 52.55 mg· hr/L, ke 0.06 hr-1, t½ 10.69 hr, Vd 17.5 L (5.1 L/kg), and CLT 17.44 mL/min.",Intravenous Ribavirin for Parainfluenza and Respiratory Syncytial Virus in an Infant Receiving Extracorporeal Membrane Oxygenation and Continuous Renal Replacement Therapy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30181726/),[h·mg] / [l],52.55,223886,DB00811,Ribavirin
,30181726,ke,"Pharmacokinetics for collection period 2 demonstrated a calculated Cmax of 10.31 mg/L, AUC0-6 of 52.55 mg· hr/L, ke 0.06 hr-1, t½ 10.69 hr, Vd 17.5 L (5.1 L/kg), and CLT 17.44 mL/min.",Intravenous Ribavirin for Parainfluenza and Respiratory Syncytial Virus in an Infant Receiving Extracorporeal Membrane Oxygenation and Continuous Renal Replacement Therapy. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30181726/),1/[h],0.06,223887,DB00811,Ribavirin
,30181726,t½,"Pharmacokinetics for collection period 2 demonstrated a calculated Cmax of 10.31 mg/L, AUC0-6 of 52.55 mg· hr/L, ke 0.06 hr-1, t½ 10.69 hr, Vd 17.5 L (5.1 L/kg), and CLT 17.44 mL/min.",Intravenous Ribavirin for Parainfluenza and Respiratory Syncytial Virus in an Infant Receiving Extracorporeal Membrane Oxygenation and Continuous Renal Replacement Therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30181726/),h,10.69,223888,DB00811,Ribavirin
,30181726,Vd,"Pharmacokinetics for collection period 2 demonstrated a calculated Cmax of 10.31 mg/L, AUC0-6 of 52.55 mg· hr/L, ke 0.06 hr-1, t½ 10.69 hr, Vd 17.5 L (5.1 L/kg), and CLT 17.44 mL/min.",Intravenous Ribavirin for Parainfluenza and Respiratory Syncytial Virus in an Infant Receiving Extracorporeal Membrane Oxygenation and Continuous Renal Replacement Therapy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30181726/),l,17.5,223889,DB00811,Ribavirin
,30181726,CLT,"Pharmacokinetics for collection period 2 demonstrated a calculated Cmax of 10.31 mg/L, AUC0-6 of 52.55 mg· hr/L, ke 0.06 hr-1, t½ 10.69 hr, Vd 17.5 L (5.1 L/kg), and CLT 17.44 mL/min.",Intravenous Ribavirin for Parainfluenza and Respiratory Syncytial Virus in an Infant Receiving Extracorporeal Membrane Oxygenation and Continuous Renal Replacement Therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30181726/),[ml] / [min],17.44,223890,DB00811,Ribavirin
,30181726,sieving coefficient,"The sieving coefficient during collection period 1 was 1.17 (range, 1.07-1.37).",Intravenous Ribavirin for Parainfluenza and Respiratory Syncytial Virus in an Infant Receiving Extracorporeal Membrane Oxygenation and Continuous Renal Replacement Therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30181726/),,1.17,223891,DB00811,Ribavirin
,4086242,half-life,"HPLC measurement of drug levels demonstrated steady-state plasma levels during the infusion, and a half-life following the infusion of 7.7 +/- 0.6 hours.","Phase I and pharmacokinetic study of tiazofurin (TCAR, NSC 286193) administered by continuous infusion. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4086242/),h,7.7,225356,DB00811,Ribavirin
,19446909,maximal,"The mean maximal decrease in HCV RNA log(10) (IU/mL) was 1.97, 2.30 and 2.46 for 400mg t.i.d., 800 mg b.i.d. and 800 mg t.i.d. doses.",Evaluation of VCH-759 monotherapy in hepatitis C infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446909/),,1.97,228908,DB00811,Ribavirin
,19446909,maximal,"The mean maximal decrease in HCV RNA log(10) (IU/mL) was 1.97, 2.30 and 2.46 for 400mg t.i.d., 800 mg b.i.d. and 800 mg t.i.d. doses.",Evaluation of VCH-759 monotherapy in hepatitis C infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446909/),,2.30,228909,DB00811,Ribavirin
,19446909,maximal,"The mean maximal decrease in HCV RNA log(10) (IU/mL) was 1.97, 2.30 and 2.46 for 400mg t.i.d., 800 mg b.i.d. and 800 mg t.i.d. doses.",Evaluation of VCH-759 monotherapy in hepatitis C infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446909/),,2.46,228910,DB00811,Ribavirin
,8572723,half-times,"These concentrations decreased after exposure, with half-times of 37-39 h.",Exposures of health-care workers to ribavirin aerosol: a pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8572723/),h,37-39,230001,DB00811,Ribavirin
,8572723,Red-cell concentrations,"Red-cell concentrations averaged 31 mumol/l on d 4, accounting for < 5% of inhaled ribavirin mass, and they remained stable for 4 d afterward.",Exposures of health-care workers to ribavirin aerosol: a pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8572723/),[μM] / [l],31,230002,DB00811,Ribavirin
,24650094,AUC(0-4h),Coinfected patients had a significantly lower RBV-AUC(0-4h) (median: 1469 μg*h/L [range 936-3677]) compared with monoinfected patients (2030 μg*h/L [851-7700]; p = 0.018).,Lower ribavirin biodisponibility in patients with HIV-HCV coinfection in comparison with HCV monoinfected patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24650094/),[h·μg] / [l],1469,237586,DB00811,Ribavirin
,24650094,AUC(0-4h),Coinfected patients had a significantly lower RBV-AUC(0-4h) (median: 1469 μg*h/L [range 936-3677]) compared with monoinfected patients (2030 μg*h/L [851-7700]; p = 0.018).,Lower ribavirin biodisponibility in patients with HIV-HCV coinfection in comparison with HCV monoinfected patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24650094/),[h·μg] / [l],2030,237587,DB00811,Ribavirin
,24650094,AUC,"This RBV under exposure in coinfected patients persisted after normalization of AUC to RBV dose per kilogram of body weight (182 μg*h/L [110-425] versus 271 μg*h/L [82-1091], p = 0.001).",Lower ribavirin biodisponibility in patients with HIV-HCV coinfection in comparison with HCV monoinfected patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24650094/),[h·μg] / [l],182,237588,DB00811,Ribavirin
,24650094,AUC,"This RBV under exposure in coinfected patients persisted after normalization of AUC to RBV dose per kilogram of body weight (182 μg*h/L [110-425] versus 271 μg*h/L [82-1091], p = 0.001).",Lower ribavirin biodisponibility in patients with HIV-HCV coinfection in comparison with HCV monoinfected patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24650094/),[h·μg] / [l],271,237589,DB00811,Ribavirin
,20923249,terminal elimination half-life,The only statistically significant difference we observed was a significant reduction in the terminal elimination half-life of fluoxetine (from 47.30 to 33.23 hours; p = 0.014) after peginterferon-α-2b treatment.,Fluoxetine disposition in patients with chronic hepatitis C treated with interferon-α. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20923249/),h,47.30,238596,DB00811,Ribavirin
,20923249,terminal elimination half-life,The only statistically significant difference we observed was a significant reduction in the terminal elimination half-life of fluoxetine (from 47.30 to 33.23 hours; p = 0.014) after peginterferon-α-2b treatment.,Fluoxetine disposition in patients with chronic hepatitis C treated with interferon-α. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20923249/),h,33.23,238597,DB00811,Ribavirin
,21357300,50% effective concentration,"INX-08189 was highly potent in replicon assays, with a 50% effective concentration of 10±6 nM against hepatitis C genotype 1b at 72 h.","INX-08189, a phosphoramidate prodrug of 6-O-methyl-2'-C-methyl guanosine, is a potent inhibitor of hepatitis C virus replication with excellent pharmacokinetic and pharmacodynamic properties. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21357300/),nM,10,244431,DB00811,Ribavirin
,21357300,50% effective concentration (EC50),"The inhibitory effect on viral replication was rapid, with a 50% effective concentration (EC50) of 35±8 nM at 24 h.","INX-08189, a phosphoramidate prodrug of 6-O-methyl-2'-C-methyl guanosine, is a potent inhibitor of hepatitis C virus replication with excellent pharmacokinetic and pharmacodynamic properties. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21357300/),nM,35,244432,DB00811,Ribavirin
,21357300,EC90,"However, the complete inhibition of S282T mutant replicons still could be achieved with an EC90 of 344±170 nM.","INX-08189, a phosphoramidate prodrug of 6-O-methyl-2'-C-methyl guanosine, is a potent inhibitor of hepatitis C virus replication with excellent pharmacokinetic and pharmacodynamic properties. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21357300/),nM,344,244433,DB00811,Ribavirin
,19852962,maximal reduction,"Plasma HCV-RNA levels dropped rapidly in all patients, with a median maximal reduction of 3.9-log(10) IU/mL and a median of 6 days to maximal reduction.",Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19852962/),[iu] / [ml],3.9,244979,DB00811,Ribavirin
,19852962,maximal reduction,"Plasma HCV-RNA levels dropped rapidly in all patients, with a median maximal reduction of 3.9-log(10) IU/mL and a median of 6 days to maximal reduction.",Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19852962/),,6,244980,DB00811,Ribavirin
,19171797,inhibition constants,"In biochemical assays using NS3/4A proteases of genotypes 1a and 1b, inhibition constants of 0.5 and 0.4 nM, respectively, were determined.","In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19171797/),nM,0.5,247510,DB00811,Ribavirin
,19171797,inhibition constants,"In biochemical assays using NS3/4A proteases of genotypes 1a and 1b, inhibition constants of 0.5 and 0.4 nM, respectively, were determined.","In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19171797/),nM,0.4,247511,DB00811,Ribavirin
,19171797,half-maximal effective concentration (EC(50)),"TMC435350 inhibited HCV replication in a cellular assay (subgenomic 1b replicon) with a half-maximal effective concentration (EC(50)) of 8 nM and a selectivity index of 5,875.","In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19171797/),nM,8,247512,DB00811,Ribavirin
,19171797,selectivity index,"TMC435350 inhibited HCV replication in a cellular assay (subgenomic 1b replicon) with a half-maximal effective concentration (EC(50)) of 8 nM and a selectivity index of 5,875.","In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19171797/),,"5,875",247513,DB00811,Ribavirin
>,19171797,tissue/plasma area under the concentration-time curve ratios,"In rats, TMC435350 was extensively distributed to the liver and intestinal tract (tissue/plasma area under the concentration-time curve ratios of >35), and the absolute bioavailability was 44% after a single oral administration.","In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19171797/),,35,247514,DB00811,Ribavirin
,19171797,absolute bioavailability,"In rats, TMC435350 was extensively distributed to the liver and intestinal tract (tissue/plasma area under the concentration-time curve ratios of >35), and the absolute bioavailability was 44% after a single oral administration.","In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19171797/),%,44,247515,DB00811,Ribavirin
,6736183,sensitivity,A sensitivity of 0.33 microM (0.08 microgram/ml) was easily achieved for 0.5-ml plasma samples.,Quantification of tiazofurin in plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6736183/),μM,0.33,252093,DB00811,Ribavirin
,6736183,sensitivity,A sensitivity of 0.33 microM (0.08 microgram/ml) was easily achieved for 0.5-ml plasma samples.,Quantification of tiazofurin in plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6736183/),[μg] / [ml],0.08,252094,DB00811,Ribavirin
,6736183,half-lives,"For a two-compartment pharmacokinetic model, the half-lives of TCAR were 18.8 and 412 min.",Quantification of tiazofurin in plasma by high-performance liquid chromatography. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6736183/),min,18.8,252095,DB00811,Ribavirin
,6736183,half-lives,"For a two-compartment pharmacokinetic model, the half-lives of TCAR were 18.8 and 412 min.",Quantification of tiazofurin in plasma by high-performance liquid chromatography. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6736183/),min,412,252096,DB00811,Ribavirin
,24815584,CLr,"Following IV administration, mean CLr was 54%, 23%, and 10% in patients with mild, moderate, and severe renal dysfunction, respectively, relative to control subjects, and was 56%, 28%, and 9% of control values after oral dosing.",Exploring the influence of renal dysfunction on the pharmacokinetics of ribavirin after oral and intravenous dosing. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24815584/),%,54,255296,DB00811,Ribavirin
,24815584,CLr,"Following IV administration, mean CLr was 54%, 23%, and 10% in patients with mild, moderate, and severe renal dysfunction, respectively, relative to control subjects, and was 56%, 28%, and 9% of control values after oral dosing.",Exploring the influence of renal dysfunction on the pharmacokinetics of ribavirin after oral and intravenous dosing. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24815584/),%,23,255297,DB00811,Ribavirin
,24815584,CLr,"Following IV administration, mean CLr was 54%, 23%, and 10% in patients with mild, moderate, and severe renal dysfunction, respectively, relative to control subjects, and was 56%, 28%, and 9% of control values after oral dosing.",Exploring the influence of renal dysfunction on the pharmacokinetics of ribavirin after oral and intravenous dosing. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24815584/),%,10,255298,DB00811,Ribavirin
,24815584,CLr,"Following IV administration, mean CLr was 54%, 23%, and 10% in patients with mild, moderate, and severe renal dysfunction, respectively, relative to control subjects, and was 56%, 28%, and 9% of control values after oral dosing.",Exploring the influence of renal dysfunction on the pharmacokinetics of ribavirin after oral and intravenous dosing. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24815584/),%,56,255299,DB00811,Ribavirin
,24815584,CLr,"Following IV administration, mean CLr was 54%, 23%, and 10% in patients with mild, moderate, and severe renal dysfunction, respectively, relative to control subjects, and was 56%, 28%, and 9% of control values after oral dosing.",Exploring the influence of renal dysfunction on the pharmacokinetics of ribavirin after oral and intravenous dosing. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24815584/),%,28,255300,DB00811,Ribavirin
,24815584,CLr,"Following IV administration, mean CLr was 54%, 23%, and 10% in patients with mild, moderate, and severe renal dysfunction, respectively, relative to control subjects, and was 56%, 28%, and 9% of control values after oral dosing.",Exploring the influence of renal dysfunction on the pharmacokinetics of ribavirin after oral and intravenous dosing. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24815584/),%,9,255301,DB00811,Ribavirin
,24815584,oral bioavailability,"Mean oral bioavailability of ribavirin was 35%, 60%, 57%, and 71% in control subjects and patients with mild, moderate, and severe renal dysfunction, respectively.",Exploring the influence of renal dysfunction on the pharmacokinetics of ribavirin after oral and intravenous dosing. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24815584/),%,35,255302,DB00811,Ribavirin
,24815584,oral bioavailability,"Mean oral bioavailability of ribavirin was 35%, 60%, 57%, and 71% in control subjects and patients with mild, moderate, and severe renal dysfunction, respectively.",Exploring the influence of renal dysfunction on the pharmacokinetics of ribavirin after oral and intravenous dosing. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24815584/),%,60,255303,DB00811,Ribavirin
,24815584,oral bioavailability,"Mean oral bioavailability of ribavirin was 35%, 60%, 57%, and 71% in control subjects and patients with mild, moderate, and severe renal dysfunction, respectively.",Exploring the influence of renal dysfunction on the pharmacokinetics of ribavirin after oral and intravenous dosing. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24815584/),%,57,255304,DB00811,Ribavirin
,24815584,oral bioavailability,"Mean oral bioavailability of ribavirin was 35%, 60%, 57%, and 71% in control subjects and patients with mild, moderate, and severe renal dysfunction, respectively.",Exploring the influence of renal dysfunction on the pharmacokinetics of ribavirin after oral and intravenous dosing. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24815584/),%,71,255305,DB00811,Ribavirin
,23939899,50% effective concentrations (EC50s),"In multiple GT1a and GT1b replicon cell lines, GS-9451 had mean 50% effective concentrations (EC50s) of 13 and 5.4 nM, respectively, with minimal cytotoxicity; similar potency was observed in chimeric replicons encoding the NS3 protease gene of GT1 clinical isolates.",Preclinical characterization of the novel hepatitis C virus NS3 protease inhibitor GS-9451. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23939899/),nM,13,255986,DB00811,Ribavirin
,23939899,50% effective concentrations (EC50s),"In multiple GT1a and GT1b replicon cell lines, GS-9451 had mean 50% effective concentrations (EC50s) of 13 and 5.4 nM, respectively, with minimal cytotoxicity; similar potency was observed in chimeric replicons encoding the NS3 protease gene of GT1 clinical isolates.",Preclinical characterization of the novel hepatitis C virus NS3 protease inhibitor GS-9451. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23939899/),nM,5.4,255987,DB00811,Ribavirin
,23939899,EC50,GS-9451 was less active in GT2a replicon cells (EC50 = 316 nM).,Preclinical characterization of the novel hepatitis C virus NS3 protease inhibitor GS-9451. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23939899/),nM,316,255988,DB00811,Ribavirin
,25645847,half-life,The terminal ribavirin half-life in plasma and phosphorylated anabolites in cells was approximately 224 h.,Population pharmacokinetic modeling of plasma and intracellular ribavirin concentrations in patients with chronic hepatitis C virus infection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25645847/),h,224,257100,DB00811,Ribavirin
,14749543,steady-state trough plasma concentration (C(pss)),"A steady-state trough plasma concentration (C(pss)) was achieved approximately 4 weeks after the initiation of treatment, but the value was scattered among patients in a range from 1100 to 4200 ng/mL.",Dosage adjustment of ribavirin based on renal function in Japanese patients with chronic hepatitis C. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749543/),[ng] / [ml],1100 to 4200,257380,DB00811,Ribavirin
,14749543,C(pss),The high C(pss) of ribavirin of approximately 4000 ng/mL decreased hemoglobin concentrations to less than 8.5 g/dL.,Dosage adjustment of ribavirin based on renal function in Japanese patients with chronic hepatitis C. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749543/),[ng] / [ml],4000,257381,DB00811,Ribavirin
,26960624,Cmax,"From the time-vs.-concentration curve, Cmax = 413.57 ng/mL, Tmax = 6.96 h, AUC = 21394.01 μg·h/mL, t1/2 = 81.61 h, and K10 = 0.0421/h were obtained.","Pharmacokinetics, efficacy prediction indexes, and residue depletion of ribavirin in Atlantic salmon's (Salmo salar) muscle after oral administration in feed. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26960624/),[ng] / [ml],413.57,259670,DB00811,Ribavirin
,26960624,Tmax,"From the time-vs.-concentration curve, Cmax = 413.57 ng/mL, Tmax = 6.96 h, AUC = 21394.01 μg·h/mL, t1/2 = 81.61 h, and K10 = 0.0421/h were obtained.","Pharmacokinetics, efficacy prediction indexes, and residue depletion of ribavirin in Atlantic salmon's (Salmo salar) muscle after oral administration in feed. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26960624/),h,6.96,259671,DB00811,Ribavirin
,26960624,AUC,"From the time-vs.-concentration curve, Cmax = 413.57 ng/mL, Tmax = 6.96 h, AUC = 21394.01 μg·h/mL, t1/2 = 81.61 h, and K10 = 0.0421/h were obtained.","Pharmacokinetics, efficacy prediction indexes, and residue depletion of ribavirin in Atlantic salmon's (Salmo salar) muscle after oral administration in feed. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26960624/),[h·μg] / [ml],21394.01,259672,DB00811,Ribavirin
,26960624,t1/2,"From the time-vs.-concentration curve, Cmax = 413.57 ng/mL, Tmax = 6.96 h, AUC = 21394.01 μg·h/mL, t1/2 = 81.61 h, and K10 = 0.0421/h were obtained.","Pharmacokinetics, efficacy prediction indexes, and residue depletion of ribavirin in Atlantic salmon's (Salmo salar) muscle after oral administration in feed. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26960624/),h,81.61,259673,DB00811,Ribavirin
,26960624,K10,"From the time-vs.-concentration curve, Cmax = 413.57 ng/mL, Tmax = 6.96 h, AUC = 21394.01 μg·h/mL, t1/2 = 81.61 h, and K10 = 0.0421/h were obtained.","Pharmacokinetics, efficacy prediction indexes, and residue depletion of ribavirin in Atlantic salmon's (Salmo salar) muscle after oral administration in feed. ","K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26960624/),1/[h],0.0421,259674,DB00811,Ribavirin
,26960624,Cmax /IC50,"Ribavirin reached adequate concentrations during the pharmacokinetic study, with prediction indexes of Cmax /IC50 = 20.7, AUC/IC50 = 1069.7, and T>IC50 = 71 h, where IC is the inhibitory concentration 50%.","Pharmacokinetics, efficacy prediction indexes, and residue depletion of ribavirin in Atlantic salmon's (Salmo salar) muscle after oral administration in feed. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26960624/),,20.7,259675,DB00811,Ribavirin
,26960624,AUC/IC50,"Ribavirin reached adequate concentrations during the pharmacokinetic study, with prediction indexes of Cmax /IC50 = 20.7, AUC/IC50 = 1069.7, and T>IC50 = 71 h, where IC is the inhibitory concentration 50%.","Pharmacokinetics, efficacy prediction indexes, and residue depletion of ribavirin in Atlantic salmon's (Salmo salar) muscle after oral administration in feed. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26960624/),,1069.7,259676,DB00811,Ribavirin
,26960624,T>IC50,"Ribavirin reached adequate concentrations during the pharmacokinetic study, with prediction indexes of Cmax /IC50 = 20.7, AUC/IC50 = 1069.7, and T>IC50 = 71 h, where IC is the inhibitory concentration 50%.","Pharmacokinetics, efficacy prediction indexes, and residue depletion of ribavirin in Atlantic salmon's (Salmo salar) muscle after oral administration in feed. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26960624/),h,71,259677,DB00811,Ribavirin
,26960624,withdrawal time,"A linear regression of the time vs. concentration was conducted, obtaining a withdrawal time of 1966 °C days.","Pharmacokinetics, efficacy prediction indexes, and residue depletion of ribavirin in Atlantic salmon's (Salmo salar) muscle after oral administration in feed. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26960624/),d·°c,1966,259678,DB00811,Ribavirin
,12934165,absorption half-life,"The absorption half-life of standard interferon alfa is 2.3 hours, while absorption half-lives for peginterferon alfa-2a and alfa-2b are 50 hours and 4.6 hours, respectively.",Pharmacokinetics of peginterferons. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12934165/),h,2.3,262256,DB00811,Ribavirin
,12934165,absorption half-lives,"The absorption half-life of standard interferon alfa is 2.3 hours, while absorption half-lives for peginterferon alfa-2a and alfa-2b are 50 hours and 4.6 hours, respectively.",Pharmacokinetics of peginterferons. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12934165/),h,50,262257,DB00811,Ribavirin
,12934165,absorption half-lives,"The absorption half-life of standard interferon alfa is 2.3 hours, while absorption half-lives for peginterferon alfa-2a and alfa-2b are 50 hours and 4.6 hours, respectively.",Pharmacokinetics of peginterferons. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12934165/),h,4.6,262258,DB00811,Ribavirin
,26952005,extraction ratio,Sofosbuvir-007 extraction ratio (52%) was consistent with historical data.,"Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26952005/),%,52,267400,DB00811,Ribavirin
,26952005,half-life,"In one patient receiving the once daily regimen, sofosbuvir-007 half-life was slightly higher (38h) than for patients with normal renal function receiving a full dose.","Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26952005/),h,38,267401,DB00811,Ribavirin
,14973309,t(max),Viramidine was orally absorbed and rapidly converted to ribavirin with a t(max) of 1.5 to 3.0 hours for both viramidine and ribavirin in plasma.,"Pharmacokinetics and safety of viramidine, a prodrug of ribavirin, in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14973309/),h,1.5 to 3.0,269070,DB00811,Ribavirin
,22781224,Cmin,"The overall median (interquartile range) ribavirin Cmin was 1.6 mg/l (1.2-2.2) with no statistical difference between abacavir users and nonusers [1.5 mg/l (0.99-2.1) and 1.7 (1.2-2.3), P = 0.15].",Ribavirin and abacavir drug interaction in HIV-HCV coinfected patients: fact or fiction? ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22781224/),[mg] / [l],1.6,269825,DB00811,Ribavirin
,22781224,Cmin,"The overall median (interquartile range) ribavirin Cmin was 1.6 mg/l (1.2-2.2) with no statistical difference between abacavir users and nonusers [1.5 mg/l (0.99-2.1) and 1.7 (1.2-2.3), P = 0.15].",Ribavirin and abacavir drug interaction in HIV-HCV coinfected patients: fact or fiction? ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22781224/),[mg] / [l],1.5,269826,DB00811,Ribavirin
,22781224,Cmin,"The overall median (interquartile range) ribavirin Cmin was 1.6 mg/l (1.2-2.2) with no statistical difference between abacavir users and nonusers [1.5 mg/l (0.99-2.1) and 1.7 (1.2-2.3), P = 0.15].",Ribavirin and abacavir drug interaction in HIV-HCV coinfected patients: fact or fiction? ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22781224/),,1.7,269827,DB00811,Ribavirin
,25801095,maximum decline,Intravenous administration of pegylated interferon resulted in a stronger and faster decline in HCV RNA than subcutaneous administration with a maximum decline of 1.17 log10 vs. 0.41 log10 or 1.32 log10 vs.,Improved pharmacodynamics and pharmacokinetics after i.v. application of peginterferon alfa-2a in hepatitis C null responders. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25801095/),log10,1.17,269870,DB00811,Ribavirin
,25801095,maximum decline,Intravenous administration of pegylated interferon resulted in a stronger and faster decline in HCV RNA than subcutaneous administration with a maximum decline of 1.17 log10 vs. 0.41 log10 or 1.32 log10 vs.,Improved pharmacodynamics and pharmacokinetics after i.v. application of peginterferon alfa-2a in hepatitis C null responders. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25801095/),log10,0.41,269871,DB00811,Ribavirin
,25801095,maximum decline,Intravenous administration of pegylated interferon resulted in a stronger and faster decline in HCV RNA than subcutaneous administration with a maximum decline of 1.17 log10 vs. 0.41 log10 or 1.32 log10 vs.,Improved pharmacodynamics and pharmacokinetics after i.v. application of peginterferon alfa-2a in hepatitis C null responders. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25801095/),log10,1.32,269872,DB00811,Ribavirin
,14712437,apparent clearance (CL/F),The mean observed ribavirin apparent clearance (CL/F) was 9.1 L/h (with an interindividual variability of 39%).,Ribavirin pharmacokinetics in renal and liver transplant patients: evidence that it depends on renal function. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14712437/),[l] / [h],9.1,270561,DB00811,Ribavirin
,10349689,time to maximum concentration,"Ribavirin is rapidly absorbed after oral administration (time to maximum concentration = 1.5 hours), followed by rapid distribution and prolonged elimination phases.",The clinical pharmacology of ribavirin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10349689/),h,1.5,272045,DB00811,Ribavirin
,10349689,absolute bioavailability,"Ribavirin appears to be extensively absorbed; however, absolute bioavailability is approximately 50%, probably due to first-pass metabolism.",The clinical pharmacology of ribavirin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10349689/),%,50,272046,DB00811,Ribavirin
,10349689,Apparent volume of distribution,"Apparent volume of distribution is extensive (approximately 2,000 L) due to ribavirin's distribution into nonplasma (cellular) compartments, which occurs via es-nucleoside transporters.",The clinical pharmacology of ribavirin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10349689/),l,"2,000",272047,DB00811,Ribavirin
,10349689,half-life,"Because of slow elimination of ribavirin from nonplasma compartments, the multiple dose half-life is approximately 298 hours.",The clinical pharmacology of ribavirin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10349689/),h,298,272048,DB00811,Ribavirin
